Antibody capable of specifically recognizing LIGHT and application thereof

Abstract

Relates to an antibody or an antigen binding fragment capable of specifically recognizing LIGHT, and a preparation method and application of the antibody or the antigen binding fragment.

Description

Antibodies specifically recognizing LIGHT and their applications

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese patent application number 202211184544.9, application date 2022.09.27, invention name “Antibodies specifically recognizing LIGHT and their applications”, and Chinese patent application number 202310861858.6, application date 2023.07.13, invention name “Antibodies specifically recognizing LIGHT and their applications”, and the entire contents of the applications are incorporated herein by reference.

[0003] Submit sequence listing as XML file

[0004] The contents of the electronic sequence listing are incorporated herein by reference in its entirety: (LIGHT_WIPO_seq.xml; size: 92KB; and creation date: 2023.07.11). Technical Field

[0005] The present invention relates to antibodies that specifically recognize LIGHT, as well as methods for preparing and using the antibodies, including methods for treating diseases and / or conditions caused by disorders of the LIGHT signaling pathway, such as autoimmune diseases and / or inflammatory diseases. Background Art

[0006] LIGHT (a lymphotoxin-like receptor inducibly expressed on T lymphocytes that competes with herpes simplex virus glycoprotein D for binding to HVEM), a member of the tumor necrosis factor superfamily (TNFSF), also known as tumor necrosis factor superfamily member 14 (TNFSF14) or CD258, is a 240-amino acid type II transmembrane protein that forms homotrimers on the cell surface. The trimeric structure of LIGHT enables it to aggregate with interacting cell surface receptors, thereby initiating the activation of costimulatory signaling pathways (Bobmer et al., 2002, Trends Biochem. Sci. 27, 19–26). Alternative splicing of LIGHT mRNA produces two isoforms: cytoplasmic LIGHT (also known as free LIGHT) and membrane-bound LIGHT (also known as cell surface LIGHT) (Morel et al., 2000, J. Immunol. 165, 4397–4404).

[0007] LIGHT is not expressed on naive T cells, but is upregulated in activated T cells. LIGHT is expressed on the surface of T cells in a strictly regulated manner after activation, appearing within 4 hours, reaching a peak at 12-24 hours, and disappearing at 48 hours (Castellano et al., 2002, J Biol Chem 277 42841-51). The activation of CD8+T cells upregulates the expression of LIGHT more than that of CD4+T cells. LIGHT is also constitutively expressed on the surface of immature dendritic cells (DCs) at a detectable level (Tamada et al., 2000, J Immunol 164 4105-10). LIGHT is also expressed in natural killer (NK) cells and monocytes (Cohavy et al., 2005, J Immunol 174 646-53).

[0008] LIGHT binds to three different receptors: lymphotoxin beta receptor (LTβR) (Crowe et al., 1994, Science 264:707-10, Browning et al., 1997, J Immunol 159:3288-98), herpes simplex virus entry mediator (HVEM) (Montgomery et al., 1996, Cell 87(3):427-36), and decoy receptor 3 (DcR3) (Yu et al., 1999, J Biol Chem 274:13733-6). Mutations of amino acids at positions 119 and 174 in the LIGHT sequence can abolish its ability to bind to HVEM and LTβR receptors (Rooney et al., 2000, J. Biol. Chem. 275:14307-14315). The signaling pathways of both LTβR and HVEM involve the recruitment of TNFR-associated factors (TRAFs) and the subsequent activation of caspases and transcription factors. Despite the similarities between these two LIGHT receptors, the downstream signaling events triggered by LTβR and HVEM are different due to their different expression patterns and binding to different signaling molecules (Zhai et al., 1998, J Clin Invest; 102(6):1142–1151).

[0009] LTβR is present on the surface of epithelial cells, stromal cells, immature DCs, and myeloid cells, but is not expressed in lymphocytes (Giles et al., 2018, Front Immunol. 9:2585). LTβR signaling induces genes involved in proinflammatory responses, including activation of MIP-1 / 2, adhesion molecules, and chemokines (Dejardin E et al., 2002, Immunity. 17(4):525). In addition, studies have reported that LIGHT-LTβR signaling controls lipid balance and plays a role in dyslipidemia (Combes JL et al., 2007, J Exp Med. 204(8):1757–1764). During normal biological development, LIGHT-LTβR interactions are considered to be an integral part of the development and maintenance of lymphoid structures (Lu et al., 2014, Front Immunol. 5:47). Scheu et al. found that the loss of LIGHT and LTβ in mice resulted in the destruction of all secondary lymphoid structures (Scheu et al., 2002, J Exp Med 195:1613-1624).

[0010] Upon binding to LIGHT, LTβR has been shown to associate with a signaling complex including TRAF2, TRAF3, and the inhibitor of κB (IκB) kinase complex (IKK). Furthermore, the LIGHT-LTβR interaction mediates activation of c-Jun N-terminal kinase (JNK), activator protein-1 (AP-1), and nuclear factor-κB (NF-κB) in a TRAF2-dependent manner (Kim WJ et al., 2005, Immunology. 114(2):272–279.). LIGHT-LTβR-mediated apoptosis appears to be dependent on TRAF3 rather than TRAF2 (Rooney IA et al., 2000, J Biol Chem. 275(19):14307–14315.). The effects of LIGHT-LTβR signaling are broad. On the one hand, the function of LIGHT-LTβR can positively regulate and support anti-tumor immune responses, including increasing the sensitivity of cancer cells to immune responses, repairing disrupted tumor vasculature, and supporting the migration and infiltration of effector cells into tumors (Joseph G. et al., Frontiers in Immonology, 2020). On the other hand, studies by Conlon TM et al. have demonstrated that therapeutic inhibition of LTβR signaling can restore lung structure from smoking-induced emphysema and airway fibrosis. Blocking LTβR signaling can block the formation of iBALT, apoptosis of alveolar epithelial cells, and restart endogenous Wnt / β-catenin-driven alveolar regeneration (Conlon TM et al., 2020, Nature. 588(7836):151-156).

[0011] Herpes simplex virus entry mediator (HVEM), also known as tumor necrosis factor receptor superfamily member 14 (TNFRSF14), was originally considered to be a mediator for herpes simplex virus type 1 to invade human or mouse cells (Montgomery, Cell 87 (3), "427-" 436, 1996). HVEM is expressed in major human tissues, with the highest expression level in hematopoietic system cells. HVEM is an insoluble transmembrane protein, including an intracellular domain, a transmembrane domain, and an extracellular domain (abbreviated as extracellular domain). The extracellular domain of HVEM includes three cysteine-rich domains (CRDs), referred to as CRD1, CRD2, and CRD3. HVEM can interact with a variety of different ligands, which transmit activation or inhibition signals to the downstream by binding to the CRD domain of HVEM. Some of these ligands deliver co-stimulatory signals, such as LIGHT and LTα; others deliver co-inhibitory signals, such as CD160, glycoprotein D (gD), and BTLA (Murphy et al., Annu Rev Immunol. 28:389, 2010). The CRD2 and CRD3 domains of HVEM interact with LIGHT (Ware et al., 2008, Immunol. Rev. 223, 186-201); BTLA and CD160 bind to CRD1 and CRD2 of HVEM and compete with HSV gD binding (Compaan et al., 2005, J. Biol. Chem. 280, 39553–39561.). Studies have reported that the deletion of the CRD1 domain leads to the transmission of costimulatory signals of HVEM-Ig, indicating that CRD1 is essential for the inhibitory signaling induced by recombinant HVEM-Ig fusion protein (Adams et al., 2002, Am. J. Transplant. 2, 12-18).

[0012] The interaction between LIGHT and HVEM is responsible for LIGHT's primary immunostimulatory properties (Steinberg et al., 2011, Immunol Rev. 244:169–87). HVEM, expressed on lymphocytes, NK cells, smooth muscle, and epithelial cells, acts as an important T cell stimulator, leading to T cell activation, proliferation, and survival (Ware CF et al., 2011, Curr Opin Immunol 23:627–31). HVEM is required for LIGHT's co-stimulatory effect, which occurs in a CD28-independent T cell-to-T cell manner, to activate T effector cells. This pro-inflammatory interaction increases the expression of the Th1 cytokines IFNγ and GM-CSF. Contact of LIGHT with HVEM induces the recruitment of TRAFs (including TRAF2) and the activation of NF-κB and JNK / AP-1 transcription factors, which contribute to T cell survival in vivo. In addition, HVEM can trigger NK cells to produce IFNγ through light-mediated nuclear factor-κB (NF-κB) RelA / p50 signaling (Fan et al., 2006, Blood 107:1342-51). Light produced by tumor-sensing NK cells is an important component of the NK-DC cascade that occurs during the initiation of a new anti-tumor response (Holmes et al., 2014, Proc Natl Acad Sci USA. 111:E5688–96). Therefore, light-HVEM-mediated T cell co-stimulation and NK-DC cascade play an important role in generating anti-tumor immunity in a therapeutic setting.

[0013] Patent application WO2008027338A2 discloses an antibody capable of specifically binding to an hLIGHT polypeptide, and a method for treating an hLIGHT-mediated disease in an individual, comprising administering an antibody, such as a fully humanized antibody, that specifically binds to an hLIGHT polypeptide to the individual.

[0014] In summary, evidence suggests that LIGHT can activate T cell- or innate immune cell-mediated inflammatory responses by binding to HVEM or LTβR receptors, leading to autoimmune and / or inflammatory diseases. Therefore, using therapeutic antibodies to antagonize LIGHT could inhibit the immune response induced by this signaling pathway, providing a new treatment for these diseases.

[0015] The disclosures of all publications, patents, patent applications, and published patent applications mentioned herein are incorporated by reference in their entirety.

[0016] Application Overview

[0017] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising a heavy chain variable domain (V H ), the V H The invention comprises: a heavy chain complementarity determining region (HC-CDR) 1 comprising GYFIN (SEQ ID NO: 1); HC-CDR2 comprising RIYPYNVX1TFYNQNFKG (SEQ ID NO: 45), wherein X1 is D or N; and HC-CDR3 comprising GTHYYGSSGAMDY (SEQ ID NO: 16); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQNVGTAVA (SEQ ID NO: 23); a LC-CDR2 comprising SASNRYT (SEQ ID NO: 30); and a LC-CDR3 comprising QQYSSYPYT (SEQ ID NO: 37).

[0018] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising V H , the V H comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1 or a variant thereof, wherein the variant comprises at most about 3 amino acid substitutions; an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 8-9 or a variant thereof, wherein the variant comprises at most about 3 amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, wherein the variant comprises at most about 3 amino acid substitutions; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:23 or a variant thereof, wherein the variant comprises substitutions of up to about 3 amino acids; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:30 or a variant thereof, wherein the variant comprises substitutions of up to about 3 amino acids; and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:37 or a variant thereof, wherein the variant comprises substitutions of up to about 3 amino acids.

[0019] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: V H , the V H Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 46-53 H Contains HC-CDR1, HC-CDR2 and HC-CDR3, as well as V L , the VL Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 62-65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0020] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:46 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 62 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (ii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:47 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (iii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:48 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (iv) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:49 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (v) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 50 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (vi) V H, which comprises V as shown in the amino acid sequence SEQ ID NO:47 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 64 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (vii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:48 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 64 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (viii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:49 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 64 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (ix) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 50 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 64 L Contains LC-CDR1, LC-CDR2 and LC-CDR3; (x) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:47 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (xi) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:48 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L LC-CDR1, LC-CDR2 and LC-CDR3 included; (xii) V H, which comprises V as shown in the amino acid sequence SEQ ID NO:49 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L LC-CDR1, LC-CDR2 and LC-CDR3 included; (xiii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 50 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (xiv) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:51 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Contains LC-CDR1, LC-CDR2 and LC-CDR3; (xv) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:52 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (xvi) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:53 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (xvii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:51 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0021] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; (ii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0022] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising an amino acid sequence as shown in any one of SEQ ID NOs: 46-53 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 46-53; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 62-65 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 62-65.

[0023] In some embodiments, an isolated anti-LIGHT antibody is provided comprising: (i) V H , comprising the amino acid sequence of SEQ ID NO: 46 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 46; and V L , comprising the amino acid sequence of SEQ ID NO: 62 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 62; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63; (iii) V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63; (iv) V H , comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63; (v) V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63; (vi) V H , comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64; (vii) V H, comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64; (viii) V H , comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64; (ix) V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64; (x) V H , comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65; (xi) V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65; (xii) V H , comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65; (xiii) V H, comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; (xiv) V H , comprising the amino acid sequence of SEQ ID NO: 51 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 51; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; (xv) V H , comprising the amino acid sequence of SEQ ID NO: 52 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 52; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65; (xvi) V H , comprising the amino acid sequence of SEQ ID NO: 53 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 53; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65; (xvii) V H , comprising the amino acid sequence of SEQ ID NO: 51 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 51; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65.

[0024] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:54 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 66 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0025] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 24, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0026] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising the amino acid sequence of SEQ ID NO: 54 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 54; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 66 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 66.

[0027] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:55 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 67 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0028] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 25, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0029] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising the amino acid sequence of SEQ ID NO: 55 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 55; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 67 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 67.

[0030] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:56 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 68 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0031] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V Lcomprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 40, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0032] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising the amino acid sequence of SEQ ID NO: 56 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 56; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 68 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 68.

[0033] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 57 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 69 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0034] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 41, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0035] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising the amino acid sequence of SEQ ID NO: 57 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 57; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 69 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 69.

[0036] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 58 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 70 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0037] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 4, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 19, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 27, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 33, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 42, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0038] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising the amino acid sequence shown in SEQ ID NO: 58 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 58; and V L, which comprises the amino acid sequence shown in SEQ ID NO: 70 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 70.

[0039] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 59 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 71 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0040] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 5, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 20, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 28, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0041] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising the amino acid sequence shown in SEQ ID NO: 59 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 59; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 71 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 71.

[0042] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising a heavy chain variable domain (V H ), the V Hcomprising a heavy chain complementarity determining region (HC-CDR) 1 comprising DHIMN (SEQ ID NO: 6); HC-CDR2 comprising RIYPVSGETNYNQKFMG (SEQ ID NO: 14); and HC-CDR3 comprising GSYYWNAMDY (SEQ ID NO: 21); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDSYMN (SEQ ID NO:29) or KASQSVDFDGESYMN (SEQ ID NO:83); a LC-CDR2 comprising SASNLES (SEQ ID NO:35); and a LC-CDR3 comprising QQSIEDPWT (SEQ ID NO:43).

[0043] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising V H , the V H comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6 or a variant thereof, wherein the variant comprises at most about 3 amino acid substitutions; an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, wherein the variant comprises at most about 3 amino acid substitutions; and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21 or a variant thereof, wherein the variant comprises at most about 3 amino acid substitutions; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence shown in any one of SEQ ID NOs:29 or 83 or a variant thereof, wherein the variant comprises a substitution of up to about 3 amino acids; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:35 or a variant thereof, wherein the variant comprises a substitution of up to about 3 amino acids; and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:43 or a variant thereof, wherein the variant comprises a substitution of up to about 3 amino acids.

[0044] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: V H , the V H Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 60, 84-85 H Contains HC-CDR1, HC-CDR2 and HC-CDR3, as well as V L , the V L Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 72, 86-91L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0045] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 60 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 72 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (ii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 84 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 86 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (iii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 85 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 87 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (iv) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 84 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 88 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (v) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 84 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 89 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (vi) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 85 HHC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO:90 L Containing LC-CDR1, LC-CDR2 and LC-CDR3; (vii) V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 84 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO:91 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0046] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs; (ii) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 83, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43, or the V LA variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0047] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising an amino acid sequence as shown in any one of SEQ ID NOs: 60, 84-85 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 60, 84-85; and V L , which comprises the amino acid sequence shown in any one of SEQ ID NOs: 72, 86-91 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 72, 86-91.

[0048] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: (i) V H , comprising the amino acid sequence shown in SEQ ID NO: 60 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 60; and V L , comprising the amino acid sequence of SEQ ID NO: 72 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 72; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , comprising the amino acid sequence of SEQ ID NO: 86 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 86; (iii) V H , comprising the amino acid sequence of SEQ ID NO: 85 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 85; and V L , comprising the amino acid sequence of SEQ ID NO: 87 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 87; (iv) V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , comprising the amino acid sequence of SEQ ID NO: 88 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 88; (v) VH , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , comprising the amino acid sequence of SEQ ID NO: 89 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 89; (vi) V H , comprising the amino acid sequence of SEQ ID NO: 85 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 85; and V L , comprising the amino acid sequence of SEQ ID NO: 90 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 90; or (vii) V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , comprising the amino acid sequence of SEQ ID NO: 91 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 91.

[0049] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising a heavy chain variable domain (V H ), the V H The heavy chain complementarity determining region (HC-CDR) 1 comprises SYNVH (SEQ ID NO: 7); HC-CDR2 comprises AVYPGNGDTSYNQKFKG (SEQ ID NO: 15); and HC-CDR3 comprises GSYYYTSSYFDH (SEQ ID NO: 22); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDSYMN (SEQ ID NO: 29); a LC-CDR2 comprising TASNLES (SEQ ID NO: 36); and a LC-CDR3 comprising QQSYEDPFT (SEQ ID NO: 44).

[0050] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: V H , the V H Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 61, 92-94 HHC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , the V L Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 73, 95-99 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0051] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , which comprises V as shown in the amino acid sequence SEQ ID NO:61 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 73 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0052] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising: (i) V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 36, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 44, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0053] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: V H , comprising an amino acid sequence as shown in any one of SEQ ID NOs: 61, 92-94 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence as shown in any one of SEQ ID NOs: 61, 92-94; and V L, which comprises the amino acid sequence shown in any one of SEQ ID NOs: 73, 95-99 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 73, 95-99.

[0054] In some embodiments, any of the isolated anti-LIGHT antibodies described above comprises: (i) V H , comprising the amino acid sequence of SEQ ID NO: 61 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 61; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 73 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 73; (ii) V H , comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , comprising the amino acid sequence of SEQ ID NO: 95 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 95; (iii) V H , comprising the amino acid sequence of SEQ ID NO: 93 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 93; and V L , comprising the amino acid sequence of SEQ ID NO: 96 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 96; (iv) V H , comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , comprising the amino acid sequence of SEQ ID NO: 96 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 96; (v) V H , comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , comprising the amino acid sequence of SEQ ID NO: 97 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 97; (vi) V H, comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , comprising the amino acid sequence of SEQ ID NO: 98 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 98; (vii) V H , comprising the amino acid sequence of SEQ ID NO: 93 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 93; and V L , comprising the amino acid sequence of SEQ ID NO: 98 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 98; (viii) V H , comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , comprising the amino acid sequence of SEQ ID NO: 98 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 98; (ix) V H , comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , comprising the amino acid sequence of SEQ ID NO: 99 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 99; or (x) V H , comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , comprising the amino acid sequence of SEQ ID NO: 99 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 99.

[0055] In some embodiments, the isolated anti-LIGHT antibody binds to human LIGHT with a Kd value of 0.1 pM to about 10 nM.

[0056] In some embodiments, an isolated anti-LIGHT antibody is provided that competes with any of the above isolated anti-LIGHT antibodies for specific binding to LIGHT. In some embodiments, an isolated anti-LIGHT antibody is provided that specifically binds to the same epitope as any of the above isolated anti-LIGHT antibodies.

[0057] In some embodiments, any of the isolated anti-LIGHT antibodies described above, the isolated anti-LIGHT antibody comprises an Fc fragment. In some embodiments, the isolated anti-LIGHT antibody is a full-length IgG antibody. In some embodiments, the isolated anti-LIGHT antibody is a full-length IgG1, IgG2, IgG3 or IgG4 antibody. In some embodiments, the isolated anti-LIGHT antibody is a chimeric, fully human or humanized antibody. In some embodiments, the isolated anti-LIGHT antibody is an antigen-binding fragment selected from Fab, Fab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, double-chain antibody (diabody) and linear antibody.

[0058] In some embodiments, an isolated nucleic acid molecule is provided, the nucleic acid molecule encoding any of the anti-LIGHT antibodies described above. In some embodiments, a vector is provided, the vector comprising any of the nucleic acid molecules described above. In some embodiments, a host cell is provided, the host cell comprising any of the anti-LIGHT antibodies described above, any of the nucleic acid molecules described above, or any of the vectors described above. In some embodiments, a method for preparing an anti-LIGHT antibody is provided, comprising: a) culturing any of the host cells described above under conditions that effectively express the anti-LIGHT antibody; and b) obtaining the expressed anti-LIGHT antibody from the host cell.

[0059] In some embodiments, a method for treating a desired individual disease or condition is provided, comprising administering to the individual an effective amount of any anti-LIGHT antibody as described above. In some embodiments, the use of any anti-LIGHT antibody as described above in the preparation of a pharmaceutical composition for treating a desired individual disease or condition is provided. In some embodiments, the use of any anti-LIGHT antibody as described above or a pharmaceutical composition comprising an anti-LIGHT antibody in the preparation of a medicament for treating a disease or condition is provided. In some embodiments, the disease or condition is related to the LIGHT signaling pathway, including autoimmune diseases and / or inflammatory diseases or conditions. In some embodiments, the disease or condition is selected from, for example, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, ankylosing spondylitis, atopic dermatitis, rheumatoid arthritis, bronchiolitis, transplant rejection, allograft rejection, graft-versus-host disease (GVHD), asthma, eosinophilic esophagitis, acute respiratory distress syndrome (ARDS), chronic heart failure, chronic obstructive pulmonary disease (COPD), septic shock, fibrotic diseases, skin fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, chronic kidney disease, systemic sclerosis, multiple sclerosis, Sjogren's syndrome, lupus, airway inflammation, psoriasis, hepatitis, celiac disease, primary biliary cirrhosis, autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenic purpura, non-alcoholic fatty liver disease, COVID19.

[0060] Also provided are pharmaceutical compositions, kits, and manufactured products comprising any of the anti-LIGHT antibodies described above. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 shows the binding affinities of chimeric anti-LIGHT antibodies to human LIGHT as analyzed by ELISA. Figure 1A shows the binding affinities of exemplary chimeric anti-LIGHT antibodies LT-m17 and LT-m18 to human LIGHT. Figure 1B shows the binding affinities of exemplary chimeric anti-LIGHT antibodies LT-m31, LT-m33, and LT-m37 to human LIGHT. Figure 1C shows the binding affinities of exemplary chimeric anti-LIGHT antibodies LT-m55, LT-m58, LT-m64, and LT-m85 to human LIGHT.

[0062] Figure 2 shows the cross-binding activity of chimeric anti-LIGHT antibodies with cynomolgus monkey LIGHT as analyzed by ELISA. Figure 2A shows the cross-binding activity of exemplary chimeric anti-LIGHT antibodies LT-m17 and LT-m18 with cynomolgus monkey LIGHT. Figure 2B shows the cross-binding activity of exemplary chimeric anti-LIGHT antibodies LT-m31, LT-m33, and LT-m37 with cynomolgus monkey LIGHT. Figure 2C shows the cross-binding activity of exemplary chimeric anti-LIGHT antibodies LT-m55, LT-m58, LT-m64, and LT-m85 with cynomolgus monkey LIGHT.

[0063] Figure 3A shows the inhibitory activity of exemplary chimeric anti-LIGHT antibodies LT-m17, LT-m31, LT-m33, and LT-m37 on activation of the LTβR reporter gene by free LIGHT. Figure 3B shows the inhibitory activity of exemplary chimeric anti-LIGHT antibodies LT-m55, LT-m58, LT-m64, and LT-m85 on activation of the LTβR reporter gene by free LIGHT.

[0064] Figure 4A shows the inhibitory activity of exemplary chimeric anti-LIGHT antibodies LT-m17, LT-m31, LT-m33, and LT-m37 on cellular LIGHT activation of the LTβR reporter gene. Figure 4B shows the inhibitory activity of exemplary chimeric anti-LIGHT antibodies LT-m55, LT-m58, and LT-m64 on cellular LIGHT activation of the LTβR reporter gene. Figure 4C shows the inhibitory activity of exemplary chimeric anti-LIGHT antibody LT-m85 on cellular LIGHT activation of the LTβR reporter gene.

[0065] Figure 5A shows the inhibitory activity of exemplary chimeric anti-LIGHT antibodies LT-m17, LT-m31, LT-m33, and LT-m37 on free LIGHT activation of the HVEM reporter gene. Figure 5B shows the inhibitory activity of exemplary chimeric anti-LIGHT antibodies LT-m55, LT-m64, and LT-m85 on free LIGHT activation of the HVEM reporter gene. Figure 5C shows the inhibitory activity of exemplary chimeric anti-LIGHT antibody LT-m58 on free LIGHT activation of the HVEM reporter gene.

[0066] Figure 6 shows the binding affinity of humanized anti-LIGHT antibodies to human LIGHT as analyzed by ELISA. Figure 6A shows the binding affinity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-1 to hum_LT-m37-6 to human LIGHT. Figure 6B shows the binding affinity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-7 to hum_LT-m37-12 to human LIGHT. Figure 6C shows the binding affinity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-13 to hum_LT-m37-16 to human LIGHT.

[0067] Figure 7 shows the activity of humanized anti-LIGHT antibodies in blocking the binding of LIGHT to LTβR as analyzed by ELISA. Figure 7A shows the activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-1, hum_LT-m37-2, hum_LT-m37-4, and hum_LT-m37-9 in blocking the binding of LIGHT to LTβR as analyzed by ELISA. Figure 7B shows the activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-5, hum_LT-m37-6, hum_LT-m37-7, hum_LT-m37-8, hum_LT-m37-11, and hum_LT-m37-12 in blocking the binding of LIGHT to LTβR as analyzed by ELISA. FIG7C shows the activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-13, hum_LT-m37-14, hum_LT-m37-15, and hum_LT-m37-16 in blocking the binding of LIGHT to LTβR as analyzed by ELISA.

[0068] Figure 8A shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies, hum_LT-m37-1 to hum_LT-m37-6, against activation of the LTβR reporter gene by free LIGHT. Figure 8B shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies, hum_LT-m37-7 to hum_LT-m37-12, against activation of the LTβR reporter gene by free LIGHT. Figure 8C shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies, hum_LT-m37-13 to hum_LT-m37-16, against activation of the LTβR reporter gene by free LIGHT.

[0069] Figure 9A shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-1 to hum_LT-m37-6 on cellular LIGHT activation of the LTβR reporter gene. Figure 9B shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-7 to hum_LT-m37-12 on cellular LIGHT activation of the LTβR reporter gene. Figure 9C shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-13 to hum_LT-m37-16 on cellular LIGHT activation of the LTβR reporter gene.

[0070] Figure 10A shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-1 to hum_LT-m37-6 on the activation of the HVEM reporter gene by free LIGHT. Figure 10B shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-14, hum_LT-m37-15, and hum_LT-m37-16 on the activation of the HVEM reporter gene by free LIGHT.

[0071] FIG11 shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-13, hum_LT-m37-14, hum_LT-m37-15, and hum_LT-m37-16 on LIGHT-induced MMP-9 production in BEAS-2B bronchial epithelial cells.

[0072] FIG12 shows the inhibitory activity of exemplary humanized anti-LIGHT antibodies hum_LT-m37-13, hum_LT-m37-14, hum_LT-m37-15, and hum_LT-m37-16 on the activation and proliferation of CD3+ T cells stimulated by LIGHT.

[0073] Figure 13 shows the inhibitory activity of exemplary anti-LIGHT antibodies on leukocyte levels in an LPS-induced mouse ARDS model. Figure 13A shows the inhibitory activity of exemplary anti-LIGHT antibodies LT-m17 and hum_LT-m37-12 on total leukocyte levels in an LPS-induced mouse ARDS model. Figure 13B shows the inhibitory activity of exemplary anti-LIGHT antibodies LT-m17 and hum_LT-m37-12 on intermediate cell levels in an LPS-induced mouse ARDS model. Figure 13C shows the inhibitory activity of exemplary anti-LIGHT antibodies LT-m17 and hum_LT-m37-12 on lymphocyte levels in an LPS-induced mouse ARDS model. Figure 13D shows the inhibitory activity of exemplary anti-LIGHT antibodies LT-m17 and hum_LT-m37-12 on neutrophil levels in an LPS-induced mouse ARDS model.

[0074] Detailed description of this application

[0075] On the one hand, the present application provides anti-LIGHT antibody molecules. Through the combination of constructed scFv phage library screening, affinity maturation, and appropriately designed biochemical and biological experiments, efficient antibody molecules that can bind to human LIGHT and inhibit the interaction of human LIGHT with its receptor have been identified. The results presented herein show that compared with the known anti-LIGHT antibody F19 (also known as CERC-002, Quisovalimab; Avalo Therapeutics), the antibodies in this application bind to different regions or epitopes of LIGHT, and surprisingly, in various biological experiments, the antibodies in this application have been shown to be even more effective than F19.

[0076] The anti-LIGHT antibodies provided herein include, for example, full-length anti-LIGHT antibodies, anti-LIGHT single-chain antibodies (scFvs), anti-LIGHT Fc fusion proteins, multispecific (eg, bispecific) anti-LIGHT antibodies, anti-LIGHT immunoconjugates, and the like.

[0077] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H The invention comprises: a heavy chain complementarity determining region (HC-CDR) 1 comprising GYFIN (SEQ ID NO: 1); HC-CDR2 comprising RIYPYNVX1TFYNQNFKG (SEQ ID NO: 45), wherein X1 is D or N; and HC-CDR3 comprising GTHYYGSSGAMDY (SEQ ID NO: 16); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQNVGTAVA (SEQ ID NO: 23); a LC-CDR2 comprising SASNRYT (SEQ ID NO: 30); and a LC-CDR3 comprising QQYSSYPYT (SEQ ID NO: 37).

[0078] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V HThe heavy chain complementarity determining region (HC-CDR) 1 comprises GYFMN (SEQ ID NO: 2); HC-CDR2 comprises RIYPYSGDTFYNQKFNN (SEQ ID NO: 10); and HC-CDR3 comprises SEHFGRNYGTGAVDY (SEQ ID NO: 17); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising RSSQGLVHSNGNTYLH (SEQ ID NO: 24); a LC-CDR2 comprising KVSNRFS (SEQ ID NO: 31); and a LC-CDR3 comprising SQSTHVPYT (SEQ ID NO: 38).

[0079] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H The heavy chain complementarity determining region (HC-CDR) 1 comprises GYFMN (SEQ ID NO: 2); HC-CDR2 comprises RIYPYSGDTFYNQKFNN (SEQ ID NO: 10); and HC-CDR3 comprises SEHFGRNYGTGAVDY (SEQ ID NO: 17); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising RSSQSLVHSNGNTYLH (SEQ ID NO: 25); a LC-CDR2 comprising KVSNRFS (SEQ ID NO: 31); and a LC-CDR3 comprising SQSTHVPLT (SEQ ID NO: 39).

[0080] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H The antibody comprises a heavy chain complementarity determining region (HC-CDR) 1 comprising NYYVY (SEQ ID NO: 3); a HC-CDR2 comprising EINPTNGDPNFNEKFKS (SEQ ID NO: 11); and a HC-CDR3 comprising SNWDYGNAMDF (SEQ ID NO: 18); and a light chain variable domain (V L ), the V LIt comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDGYMN (SEQ ID NO: 26); a LC-CDR2 comprising KASHLDS (SEQ ID NO: 32); and a LC-CDR3 comprising QQSIEDPLT (SEQ ID NO: 40).

[0081] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H The antibody comprises a heavy chain complementarity determining region (HC-CDR) 1 comprising NYYVY (SEQ ID NO: 3); a HC-CDR2 comprising EINPTNGDPNFNEKFKS (SEQ ID NO: 11); and a HC-CDR3 comprising SNWDYGNAMDF (SEQ ID NO: 18); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDGYMN (SEQ ID NO: 26); a LC-CDR2 comprising KASHLDS (SEQ ID NO: 32); and a LC-CDR3 comprising QQSIEDPFT (SEQ ID NO: 41).

[0082] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H The heavy chain complementarity determining region (HC-CDR) 1 comprises NYGMN (SEQ ID NO: 4); HC-CDR2 comprises WINTYTGEPTYADDFKG (SEQ ID NO: 12); and HC-CDR3 comprises DNWDGKGMDY (SEQ ID NO: 19); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQDVDTAVA (SEQ ID NO: 27); a LC-CDR2 comprising WASTRHT (SEQ ID NO: 33); and a LC-CDR3 comprising HQYGSYPLT (SEQ ID NO: 42).

[0083] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V Hcomprising: a heavy chain complementarity determining region (HC-CDR) 1 comprising TYYMY (SEQ ID NO: 5); HC-CDR2 comprising EINPTNGGTIFNEKFKT (SEQ ID NO: 13); and HC-CDR3 comprising GNWPYWSFDV (SEQ ID NO: 20); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDNYMN (SEQ ID NO: 28); a LC-CDR2 comprising AASNLDS (SEQ ID NO: 34); and a LC-CDR3 comprising QQSIEDPWT (SEQ ID NO: 43).

[0084] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H The heavy chain complementarity determining region (HC-CDR) 1 comprises DHIMN (SEQ ID NO: 6); HC-CDR2 comprises RIYPVSGETNYNQKFMG (SEQ ID NO: 14); and HC-CDR3 comprises GSYYWNAMDY (SEQ ID NO: 21); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDSYMN (SEQ ID NO:29) or KASQSVDFDGESYMN (SEQ ID NO:83); a LC-CDR2 comprising SASNLES (SEQ ID NO:35); and a LC-CDR3 comprising QQSIEDPWT (SEQ ID NO:43).

[0085] On the other hand, the present application provides an anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H The heavy chain complementarity determining region (HC-CDR) 1 comprises SYNVH (SEQ ID NO: 7); HC-CDR2 comprises AVYPGNGDTSYNQKFKG (SEQ ID NO: 15); and HC-CDR3 comprises GSYYYTSSYFDH (SEQ ID NO: 22); and a light chain variable domain (V L ), the V LIt comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDSYMN (SEQ ID NO: 29); a LC-CDR2 comprising TASNLES (SEQ ID NO: 36); and a LC-CDR3 comprising QQSYEDPFT (SEQ ID NO: 44).

[0086] Also provided are nucleic acids encoding anti-LIGHT antibodies, compositions comprising anti-LIGHT antibodies, and methods of making and using anti-LIGHT antibodies.

[0087] definition

[0088] As used herein, "treatment" or "treating" is a method of obtaining beneficial or desired results, including clinical results. For the purposes of this application, the beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms caused by the disease, reducing the extent of the disease, stabilizing the disease (e.g., preventing or delaying worsening of the disease), preventing or delaying the spread of the disease (e.g., metastasis), preventing or delaying recurrence of the disease, delaying or slowing the progression of the disease, improving the disease state, alleviating the disease (partially or completely), reducing the dose of one or more other drugs required to treat the disease, delaying disease progression, improving or enhancing the quality of life, increasing body weight, and / or prolonging survival. At the same time, "treatment" also includes a reduction in the pathological consequences of the disease (e.g., forced expiratory volume for asthma). The methods of the present application contemplate any one or more aspects of these treatments.

[0089] The term "antibody" includes full-length antibodies and antigen-binding fragments thereof. Full-length antibodies include two heavy chains and two light chains. The variable regions of the light and heavy chains are responsible for antigen binding. The variable regions in both chains typically include three hypervariable loops, known as complementarity determining regions (CDRs) (light chain (LC) CDRs include LC-CDR1, LC-CDR2, and LC-CDR3, and heavy chain (HC) CDRs include HC-CDR1, HC-CDR2, and HC-CDR3). The CDR boundaries of the antibodies or antigen-binding fragments disclosed herein can be defined or identified by the Kabat, Chothia, or Al-Lazikani conventions (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). The three CDR regions of the heavy or light chain are inserted between flanking segments called framework regions (FRs), which are more highly conserved than the CDR regions and form a scaffold that supports the hypervariable loops. The constant regions of the heavy and light chains are not involved in antigen binding but exhibit various effector functions. Antibodies are classified based on the amino acid sequence of their heavy chain constant regions. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by having heavy chains of type α, δ, ε, γ, and μ, respectively. Several major antibody classes are divided into subclasses, such as IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgA1 (α1 heavy chain), or IgA2 (α2 heavy chain).

[0090] As used herein, the term "antigen-binding fragment" includes antibody fragments, such as diabodies, Fab, Fab', F(ab')2, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabodies (dsdiabodies), single-chain Fv (scFv), scFv dimers (divalent diabodies), multispecific antibodies composed of antibody fragments comprising one or more CDRs, single-domain antibodies, nanobodies, domain antibodies, bivalent domain antibodies, or any other antibody fragment that can bind to an antigen but does not contain a complete antibody structure. Antigen-binding fragments can bind to the same antigen as a parent antibody or parent antibody fragment (such as a parent scFv). Antigen-binding fragments also include fusion proteins comprising the above-mentioned antibody fragments. In some embodiments, an antigen-binding fragment may include one or more CDRs from a specific human antibody that are transplanted to a framework region from one or more different human antibodies.

[0091] As used herein, the term "epitope" refers to a specific group of atoms or amino acids on an antigen to which an antibody or antibody portion binds. If two antibodies or antibody portions exhibit competitive binding to an antigen, they likely bind to the same epitope on the antigen.

[0092] As used herein, a first antibody "competes" for binding to a second antibody for a LIGHT target when the first antibody inhibits binding of the second antibody to the LIGHT target by at least 50% (e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) at equimolar concentrations, and vice versa. PCT Publication WO 03 / 48731 describes a high-throughput antibody "epitope binning" method based on cross-competition.

[0093] As used herein, the terms "specifically bind," "specifically recognize," or "specific for" refer to a measurable and reproducible interaction, e.g., binding of an antibody to a target that can confirm the presence of the target in a heterogeneous population of molecules, including biomolecules. For example, an antibody that specifically recognizes a target (which may be an epitope) means that the antibody binds to the target with greater affinity, avidity, more readily, and / or more persistently than it binds to other targets. In some embodiments, an antibody that specifically recognizes an antigen reacts with one or more antigenic determinants of the antigen with an affinity that is at least 10 times greater than its binding affinity to other targets.

[0094] As used herein, an "isolated" anti-LIGHT antibody refers to an anti-LIGHT antibody that (1) is not related to a naturally occurring protein, (2) does not contain other proteins from the same source, (3) is expressed by cells of a different species, or (4) does not exist in nature.

[0095] As used herein, the term "isolated nucleic acid" refers to a nucleic acid of genomic, cDNA, or synthetic origin, or a combination thereof. Depending on its origin, the "isolated nucleic acid" is (1) unrelated to all or part of the polynucleotide sequence found in nature, (2) operably linked to a polynucleotide sequence with which it is not naturally associated, or (3) not found in nature as part of a longer sequence.

[0096] As used herein, the term "CDR" or "complementarity determining region" refers to the non-contiguous antigen binding sites found within the variable domains of heavy and light chain polypeptides. In the literature Kabat et al., J. Biol. Chem. 252: 6609-6616 (1977); Kabat et al., USDept. of Health and Human Services, "Sequences of proteins of immunological interest" (1991); Chothia et al., J. Mol. Biol. 196: 901-917 (1987); Al-Lazikani B. et al. al., J. Mol. Biol., 273: 927-948 (1997); MacCallum et al., J. Mol. Biol. 262: 732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832- 3839 (2008); Lefranc MPet These specific regions are described in, for example, Desmond et al., Dev. Comp. Immunol., 27:55-77 (2003); and Honegger and Plückthun, J. Mol. Biol., 309:657-670 (2001), where these definitions include overlap or subsets of amino acid residues when compared to one another. However, any definition used to designate a CDR of an antibody, grafted antibody, or variant thereof is included within the scope of the term as defined and used herein. Table 1 lists the positions of the amino acid residues included in the CDRs defined by the various references cited above for comparison. Algorithms and binding interfaces for CDR prediction are known in the art, including, for example, Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Ehrenmann F. et al., Nucleic Acids Res., 38: D301-D307 (2010); and Adolf-Bryfogle J. et al., Nucleic Acids Res., 43: D432-D438 (2015). The contents of the references cited in this paragraph are incorporated herein by reference in their entirety for use in this application and in one or more claims that may be included in this article.

[0097] Table 1: CDR definitions 1 The amino acid residue numbers refer to the nomenclature of Kabat et al.2 The amino acid residue numbers refer to the nomenclature of Chothia et al. 3 The amino acid residue numbers refer to the nomenclature of MacCallum et al. 4 The amino acid residue numbers refer to the nomenclature of Lefranc et al. 5 The amino acid residue numbers refer to the nomenclature of Honegger and Plückthun.

[0098] The term "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical or homologous to the corresponding sequence in an antibody from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they have the biological activity described in the present application (see US Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984)).

[0099] "Fv" is the smallest antibody fragment that contains a complete antigen recognition and binding site. This fragment is a dimer formed by a heavy chain variable domain and a light chain variable domain tightly non-covalently linked. Six hypervariable loops (3 loops each in the light chain and heavy chain) are derived from the folding of these two domains. The hypervariable loops provide the antibody with amino acid residues for binding to the antigen and confer specificity for binding to the antibody. However, even a single variable domain (or half of an Fv fragment, which only contains 3 CDRs specific for the antigen) has the ability to recognize and bind to the antigen, although its affinity is lower than that of the complete binding site.

[0100] "Single-chain Fv", also abbreviated as "sFv" or "scFv", is a Fv that contains V molecules linked into a single polypeptide chain. H and V L In some embodiments, the scFv polypeptide further comprises a V H and V L The linker polypeptide between the domains allows the scFv to form an ideal structure for antigen binding. For an overview of scFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

[0101] The term "diabody" is used in V H and V L A small antibody fragment is prepared by constructing scFv fragments (see above) using short linkers (e.g., 5-10 residues) between the domains. This allows the variable domains to pair between chains rather than within the chain, resulting in a bivalent fragment, that is, a fragment with two antigen-binding sites. Bispecific diabodies are heterodimers of two "crossover" scFv fragments, in which the V domains of the two antibodies are H and V L The domains are located on different polypeptide chains. Diabodies are fully described in EP 404,097; WO 93 / 11161; Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

[0102] The "humanized" form of a non-human (such as a rodent) antibody is a chimeric antibody that includes minimal sequences from a non-human antibody. In most cases, a humanized antibody is a human immunoglobulin (recipient antibody) in which the hypervariable region (HVR) residues of the recipient antibody are replaced by hypervariable region residues from a non-human species such as a mouse, rat, rabbit or non-human mammal with ideal antibody specificity, affinity and performance (donor antibody). In some cases, residues in the human immunoglobulin framework region are replaced by corresponding non-human residues. In addition, a humanized antibody may include residues that are not present in either the recipient antibody or the donor antibody. These modifications can further improve the performance of the antibody. Typically, a humanized antibody will comprise substantially all, at least one, and usually two variable domains, wherein all or substantially all of the hypervariable loops correspond to the hypervariable loops of a non-human immunoglobulin, and all or substantially all of the framework regions are human immunoglobulin sequences. The human antibody optionally also comprises at least a portion of an immunoglobulin constant region (Fc), typically a constant region of a human immunoglobulin. For details, see Jones et al., Nature 321: 522-525 (1986); Riechmann et al., Nature 332: 323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2: 593-596 (1992).

[0103] The "percent (%) amino acid sequence identity" or "homology" of the polypeptide and antibody sequences identified herein is defined as the percentage of identical amino acid residues in a candidate sequence and the polypeptide sequence being compared, when the sequences are aligned, considering conservative substitutions as part of the sequence identity. Percent amino acid sequence identity can be determined by various alignment methods within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm needed to maximize alignment over the full length of the sequences being compared. However, for the purposes of this article, percent amino acid sequence identity values ​​are generated using the sequence alignment computer program MUSCLE (Edgar, RC, Nucleic Acids Research 32(5):1792-1797, 2004; Edgar, RC, BMC Bioinformatics 5(1):113, 2004).

[0104] The term "Fc receptor" or "FcR" is used to describe a receptor that binds to the Fc region of an antibody. In some embodiments, the FcR described herein is an FcR that binds to an IgG antibody (a gamma receptor), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced ​​forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences and differ primarily in the cytoplasmic domain. The cytoplasmic domain of the activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM). The cytoplasmic domain of the inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) (see M.in Annu. Rev. Immunol. 15:203-234 (1997). The term also includes allotypes, such as the FcγRIIIA allotypes: FcγRIIIA-Phe158, FcγRIIIA-Val158, FcγRIIA-R131, and / or FcγRIIA-H131. FcRs are described in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991) and Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). The term FcR in this application encompasses other types of FcRs, including those identified in the future. The term FcR also includes the neonatal receptor FcRn, which is responsible for the transfer of maternal IgGs to the newborn (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).

[0105] The term "FcRn" refers to the neonatal Fc receptor (FcRn). FcRn is structurally similar to the major histocompatibility complex (MHC) and consists of an α chain non-covalently bound to β2 microglobulin. The various functions of the neonatal Fc receptor FcRn are reviewed in Ghetie and Ward (2000) Annu. Rev. Immunol. 18, 739-766. FcRn plays an important role in the passive transport of immunoglobulins (IgGs) from mother to newborn and in regulating serum IgG levels. As a salvage receptor, FcRn can bind and transport endocytosed IgGs in their intact form within and between cells, protecting them from the default degradation pathway.

[0106] The "CH1 domain" of a human IgG heavy chain constant region typically stretches from amino acid 118 to amino acid 215 (EU numbering system).

[0107] The "hinge region" is generally defined as stretching from Glu 216 to Pro 230 of human IgG1 (Burton, Molec. Immunol. 22: 161-206 (1985)). By placing the first and last cysteine ​​residues that form inter-heavy chain disulfide bonds in the same positions as in IgG1, the hinge regions of other IgG isotypes can be aligned with the IgG1 sequence.

[0108] The "CH2 domain" of the human IgG Fc region typically extends from amino acids 231 to 340. The CH2 domain is unique in that it does not closely pair with another domain. Instead, two N-terminally linked branched sugar chains are inserted between the two CH2 domains of the intact native IgG molecule. It is hypothesized that carbohydrates may serve as a substitute for domain-to-domain pairing, helping to maintain CH2 domain stability. Burton, Molec. Immunol. 22:161-206 (1985).

[0109] The "CH3" domain includes the CH2 domain extending from the C-terminal residue within the Fc region (from amino acid 341 to the C-terminus of the antibody sequence, usually amino acid residue 446 or 447 in IgG).

[0110] A "functional Fc fragment" possesses the "effector functions" of a native Fc region sequence. Exemplary "effector functions" include C1q binding; complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and downregulation of cell surface receptors (e.g., B cell receptor; BCR). Such effector functions generally require the Fc region to be bound to a binding domain (e.g., an antibody variable region) and can be assessed using a variety of experimental methods known in the art.

[0111] IgG Fc variant antibodies with "altered" FcR binding affinity or ADCC activity have increased or decreased FcR binding activity and / or ADCC activity compared to the parent polypeptide or a polypeptide comprising a native Fc sequence. Fc variants that exhibit "enhanced binding" to FcRs have a higher binding affinity (e.g., lower apparent Kd or IC) to at least one FcR compared to the parent polypeptide or a polypeptide comprising a native IgG Fc sequence. 50 In some embodiments, the binding capacity is enhanced by 3-fold, e.g., 5-, 10-, 25-, 50-, 60-, 100-, 150-, 200-, or even up to 500-fold, or the binding capacity is increased by 25% to 1000%, compared to the parent polypeptide. An Fc variant that exhibits "reduced binding" to an FcR has a lower affinity for at least one FcR (e.g., a higher apparent Kd or IC) than the parent polypeptide. 50 Compared with the parent polypeptide, its binding capacity is reduced by 40% or more.

[0112] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" is a form of cytotoxicity that refers to the binding of secreted Ig to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages), enabling these cytotoxic effector cells to specifically bind to target cells bearing antigen and subsequently kill the target cells using cytotoxins. Antibodies "arm" the cytotoxic cells and are required for this killing. Of the major cell types that mediate ADCC, NK cells express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. The expression of FcRs on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess the ADCC activity of a target molecule, an in vitro ADCC assay can be performed, as described in U.S. Patent Nos. 5,500,362 or 5,821,337. Effector cells suitable for such experiments include peripheral blood mononuclear cells (PBMC) and natural killer cells (NK). Alternatively, or in addition, the ADCC activity of the target molecule can also be assessed in vivo, for example, as described in the animal model disclosed in Clynes et al. PNAS (USA) 95: 652-656 (1998).

[0113] Polypeptides comprising Fc region variants exhibit "enhanced ADCC activity" or are capable of more effectively mediating ADCC in the presence of human effector cells, compared to polypeptides comprising wild-type IgG Fc polypeptides or parent polypeptides. When tested in substantially the same quantity as polypeptides comprising wild-type IgG Fc polypeptides (or parent polypeptides), such polypeptides comprising Fc region variants are capable of more effectively mediating ADCC, both in vitro and in vivo. Such variants are generally identified using any in vitro ADCC assay known in the art, such as assays or methods for identifying ADCC activity, such as in animal models. In some embodiments, such variants mediate ADCC 5- to 100-fold more efficiently, such as 25- to 50-fold more efficiently, than wild-type Fc (or parent polypeptide).

[0114] "Complement-dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (Clq) to an antibody (of the appropriate structural subclass) that binds to the cognate antigen. To assess complement activation, a CDC assay, such as that described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996), can be performed. Polypeptide variants with altered Fc region amino acid sequences and increased or decreased Clq binding capacity are described in U.S. Patent No. 6,194,551 Bl and WO99 / 51642. The contents of these patent publications are expressly incorporated herein by reference. See also Idusogie et al. J. Immunol. 164:4178-4184 (2000).

[0115] Unless otherwise indicated, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence. A nucleotide sequence encoding a protein or RNA may also include introns, for example, a nucleotide sequence encoding a protein may contain introns in some forms.

[0116] The term "operably linked" refers to a functional connection between a regulatory sequence and a heterologous nucleotide sequence, thereby enabling expression of the latter. For example, a first nucleotide sequence is operably linked to a second nucleotide sequence when the first nucleotide sequence is in a functional relationship with the second nucleotide sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, if necessary, can link two protein coding regions in the same reading frame.

[0117] "Homologous" refers to the sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. If the same base or amino acid monomer subunit is present at the same position in two compared sequences, for example, adenine is present at the same position in two DNA molecules, then the two DNA molecules are homologous at that position. The percentage homology between two sequences refers to the ratio of the number of matching or homologous positions shared by the two sequences to the total number of positions multiplied by 100. For example, if 6 out of 10 positions in two sequences are matched or homologous, then the homology between the two sequences is 60%. For example, the DNA sequences ATTGCC and TATGGC have 50% homology. Generally speaking, when aligning two sequences, the comparison is performed with the goal of obtaining maximum homology.

[0118] An "effective amount" of an anti-LIGHT antibody or composition disclosed herein is an amount sufficient to achieve a specific purpose. An "effective amount" can be determined empirically and by known methods related to the purpose.

[0119] The term "therapeutically effective amount" refers to an amount of an anti-LIGHT antibody or composition disclosed herein that is effective in treating a disease or symptom in an individual. For example, in the case of asthma, "asthma-related parameters" are used as indicators for evaluating the effectiveness of asthma treatment, for example, "asthma-related parameters" include: (a) forced expiratory volume in 1 second (FEV1); (b) peak expiratory flow (PEF), including morning PEF (AM PEF) and evening PEF (PM PEF); (c) use of inhaled bronchodilators, such as albuterol or levalbuterol; (d) five-item Asthma Control Questionnaire (ACQ5) score; (d) nocturnal awakenings; and (e) 22-item Sino-Nasal Outcome Test (SNOT-22) score. The therapeutically effective amount of an anti-LIGHT antibody or composition disclosed herein can increase one or more of FEV1, AM PEF, or PM PEF from baseline, and / or reduce one or more of daily albuterol / levalbuterol usage, ACQ5 score, average number of awakenings at night, or SNOT-22 score from baseline. As used herein, the term "baseline" refers to the value of an asthma-related parameter in a patient before or at the time of taking the pharmaceutical composition of the present invention. In some embodiments, an improvement in an asthma-related parameter refers to an increase in FEV1 of at least 0.10 L from baseline. In some embodiments, an improvement in an asthma-related parameter refers to an increase in AM PEF of at least 10.0 L / min from baseline. In some embodiments, an improvement in an asthma-related parameter refers to an increase in PM PEF of at least 1.0 L / min from baseline. In some embodiments, an improvement in an asthma-related parameter refers to a reduction in albuterol / levalbuterol usage of at least 1 puff(s) per day from baseline. In some embodiments, an improvement in an asthma-related parameter refers to a decrease in ACQ5 score of at least 0.5 points from baseline. In some embodiments, an improvement in an asthma-related parameter is a decrease in the number of nocturnal awakenings by at least 0.2 from baseline. In some embodiments, an improvement in an asthma-related parameter is a decrease in the SNOT-22 score by at least 5 points from baseline. In some embodiments, a therapeutically effective amount is an amount that adequately controls the disease. In some embodiments, a therapeutically effective amount is an amount that prolongs a patient's survival. In certain embodiments, a therapeutically effective amount is an amount that improves a patient's progression-free survival.

[0120] As used herein, "pharmaceutically acceptable" or "pharmacologically compatible" refers to a material that is free of biological activity or other undesirable properties, e.g., a material that can be added to a pharmaceutical composition administered to a patient without causing a significant adverse biological reaction, or that does not interact in a deleterious manner with any other component contained in the composition. Pharmaceutically acceptable carriers or excipients preferably meet the required standards for toxicology or manufacturing testing and / or are included in the inactive ingredient guide compiled by the U.S. Food and Drug Administration.

[0121]

[0066] The embodiments of the present application described herein should be understood to include "consisting of" and / or "consisting essentially of" embodiments.

[0122] Reference herein to "about" for a value or parameter includes (and describes) variations of the value or parameter itself. For example, a description involving "about X" includes a description of "X".

[0123] As used herein, reference to "not" a value or parameter generally indicates and describes "other than" a value or parameter. For example, "the method cannot be used to treat type X cancer" means that the method is generally used to treat other types of cancer besides type X cancer.

[0124] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0125] Anti-LIGHT antibody

[0126] On the one hand, the present application provides anti-human and / or cynomolgus monkey LIGHT antibodies that specifically bind to LIGHT. The anti-LIGHT antibodies include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibody molecules comprising heavy and / or light chain CDRs as described herein. On the one hand, the present application provides antibodies separated from LIGHT. Expected anti-LIGHT antibodies include, for example, full-length anti-LIGHT antibodies (such as full-length IgG1 or IgG4), anti-LIGHT single-chain antibodies, anti-LIGHT Fc fusion proteins, multispecific (such as bispecific) anti-LIGHT antibodies, anti-LIGHT immunoconjugates, and the like. In some embodiments, the anti-LIGHT antibody is a full-length antibody (such as full-length IgG1 or IgG4) or an antigen-binding fragment thereof that specifically binds to LIGHT. In some embodiments, the anti-LIGHT antibody is Fab, Fab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, double-chain antibody (diabody) or linear antibody. In some embodiments, an antibody that specifically binds to LIGHT means that the affinity of the antibody for binding to LIGHT is at least 10 times greater than the affinity for binding to a non-target (e.g., 10 ... 2 , 10 3 , 10 4 , 10 5 , 10 6 , or 10 7 times). In some embodiments, non-target refers to an antigen that is not LIGHT. Binding affinity can be determined by methods known in the art, such as ELISA, fluorescence-activated cell sorting (FACS) analysis, or radioimmunoprecipitation assay (RIA). Kd values ​​can be determined by methods known in the art, such as surface plasmon resonance (SPR) or biolayer interferometry (BLI).

[0127] Although anti-LIGHT antibodies comprising human sequences (e.g., human heavy and light chain variable domains comprising human CDR sequences) are discussed extensively herein, non-human anti-LIGHT antibodies are also contemplated. In some embodiments, non-human anti-LIGHT antibodies comprise human CDR sequences of the anti-LIGHT antibodies described herein and non-human framework region sequences. In some embodiments, non-human framework region sequences include any sequence for generating heavy and / or light chain variable domains using one or more human CDR sequences as described herein, including, for example, mammals such as mice, rats, rabbits, pigs, cattle (e.g., cattle, bulls, buffaloes), deer, sheep, goats, chickens, cats, dogs, ferrets, primates (e.g., small apes, macaques), etc. In some embodiments, non-human anti-LIGHT antibodies include anti-LIGHT antibodies generated by grafting one or more human CDR sequences described herein into non-human framework regions (e.g., mouse or chicken framework region sequences).

[0128] The amino acid sequence of an exemplary human LIGHT comprises or consists of the amino acid sequence shown in SEQ ID NO:78.

[0129] In some embodiments, the anti-LIGHT antibodies described herein specifically recognize an epitope in human LIGHT. In some embodiments, the anti-LIGHT antibodies cross-react with LIGHT from species other than human. In some embodiments, the anti-LIGHT antibodies are completely specific for human LIGHT and do not cross-react with other non-human species.

[0130] In some embodiments, the anti-LIGHT antibody cross-reacts with at least one allelic variant of a LIGHT protein (or a fragment thereof). In some embodiments, the allelic variant has up to 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30) amino acid substitutions (e.g., conservative substitutions) compared to a naturally occurring LIGHT protein (or a fragment thereof). In some embodiments, the anti-LIGHT antibody does not cross-react with any allelic variant of a LIGHT protein (or a fragment thereof).

[0131] In some embodiments, the anti-LIGHT antibody cross-reacts with at least one interspecies variant of the LIGHT protein. In some embodiments, for example, the LIGHT protein (or its fragment) is human LIGHT, and the interspecies variant of the LIGHT protein (or its fragment) is a variant in cynomolgus monkeys. In some embodiments, the anti-LIGHT antibody does not cross-react with any interspecies variant of the LIGHT protein.

[0132] In some embodiments, as described herein, any anti-LIGHT antibody comprises an antibody heavy chain constant region and an antibody light chain constant region. In some embodiments, the anti-LIGHT antibody comprises an IgG1-type heavy chain constant region. In some embodiments, the anti-LIGHT antibody comprises an IgG2-type heavy chain constant region. In some embodiments, the anti-LIGHT antibody comprises an IgG3-type heavy chain constant region. In some embodiments, the anti-LIGHT antibody comprises an IgG4-type heavy chain constant region. In some embodiments, the heavy chain constant region comprises (includes, consists of, or consists essentially of) the amino acid sequence of SEQ ID NO: 74. In some embodiments, the heavy chain constant region comprises (includes, consists of, or consists essentially of) the amino acid sequence of SEQ ID NO: 75. In some embodiments, the anti-LIGHT antibody comprises a kappa light chain constant region. In some embodiments, the light chain constant region comprises (includes, consists of, or consists essentially of) the amino acid sequence of SEQ ID NO: 76. In some embodiments, the anti-LIGHT antibody comprises a lambda light chain constant region. In some embodiments, the light chain constant region comprises (includes, consists of, or consists essentially of) the amino acid sequence of SEQ ID NO: 77. In some embodiments, the anti-LIGHT antibody comprises an antibody heavy chain variable domain and an antibody light chain variable domain.

[0133] In some embodiments, the anti-LIGHT antibody comprises a heavy chain variable domain (V H ), the V H The invention comprises: a heavy chain complementarity determining region (HC-CDR) 1 comprising GYFIN (SEQ ID NO: 1); HC-CDR2 comprising RIYPYNVX1TFYNQNFKG (SEQ ID NO: 45), wherein X1 is D or N; and HC-CDR3 comprising GTHYYGSSGAMDY (SEQ ID NO: 16); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQNVGTAVA (SEQ ID NO: 23); a LC-CDR2 comprising SASNRYT (SEQ ID NO: 30); and a LC-CDR3 comprising QQYSSYPYT (SEQ ID NO: 37).

[0134] In some embodiments, the anti-LIGHT antibody comprises V H , the V Hcomprising: an HC-CDR1 comprising the amino acid sequence shown in SEQ ID NO: 1 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; an HC-CDR2 comprising the amino acid sequence shown in any one of SEQ ID NOs: 8-9 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and an HC-CDR3 comprising the amino acid sequence shown in SEQ ID NO: 16 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids.

[0135] In some embodiments, the anti-LIGHT antibody comprises V H , the V H It comprises: HC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO: 1, HC-CDR2, which comprises the amino acid sequence shown in any one of SEQ ID NOs: 8-9, and HC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO: 16.

[0136] In some embodiments, the anti-LIGHT antibody comprises V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:23 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:30 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids; and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:37 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids.

[0137] In some embodiments, the anti-LIGHT antibody comprises V L , the V L It comprises: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:23, LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:30, and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:37.

[0138] In some embodiments, the anti-LIGHT antibody comprises V H , the V Hcomprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 8-9 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:23 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:30 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids; and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:37 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids.

[0139] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 8-9, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and V L , the V L It comprises: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:23, LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:30, and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:37.

[0140] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V Lcomprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0141] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:23, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:30, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:37.

[0142] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0143] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and V L , the V LIt comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:23, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:30, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:37.

[0144] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising V as shown in any one of the amino acid sequences shown in SEQ ID NOs: 46-53 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , the V L Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 62-65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0145] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:46 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 62 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0146] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:47 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0147] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:48 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0148] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:49 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0149] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 50 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0150] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:47 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 64 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0151] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:48 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 64 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0152] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:49 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 64 LContains LC-CDR1, LC-CDR2 and LC-CDR3.

[0153] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 50 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 64 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0154] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:47 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0155] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:48 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0156] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:49 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0157] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 50 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L, which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0158] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:51 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 63 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0159] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:52 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0160] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:53 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0161] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:51 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 65 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0162] In some embodiments, the anti-LIGHT antibody comprises: V H , the V Hcomprising an amino acid sequence as set forth in any one of SEQ ID NOs: 46-53 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 46-53; and V L , the V L comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 62-65 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 62-65. In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 46-53, and V L , the V L Comprising the amino acid sequence shown in any one of SEQ ID NOs: 62-65.

[0163] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 46 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 46; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 62 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 46, and V L , the V L Comprising the amino acid sequence SEQ ID NO:62.

[0164] In some embodiments, the anti-LIGHT antibody comprises: V H , the V Hcomprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 47, and V L , the V L Comprising the amino acid sequence SEQ ID NO:63.

[0165] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 48, and V L , the V L Comprising the amino acid sequence SEQ ID NO:63.

[0166] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , the V Lcomprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 49, and V L , the V L Comprising the amino acid sequence SEQ ID NO:63.

[0167] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 50, and V L , the V L Comprising the amino acid sequence SEQ ID NO:63.

[0168] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-LIGHT antibody comprises V H , the VH Comprising the amino acid sequence SEQ ID NO: 47, and V L , the V L Comprising the amino acid sequence SEQ ID NO:64.

[0169] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 48, and V L , the V L Comprising the amino acid sequence SEQ ID NO:64.

[0170] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 49, and V L , the V L Comprising the amino acid sequence SEQ ID NO:64.

[0171] In some embodiments, the anti-LIGHT antibody comprises: V H, the V H comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 64. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 50, and V L , the V L Comprising the amino acid sequence SEQ ID NO:64.

[0172] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 47, and V L , the V L Comprising the amino acid sequence SEQ ID NO:65.

[0173] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , the VL comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 48, and V L , the V L Comprising the amino acid sequence SEQ ID NO:65.

[0174] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 49, and V L , the V L Comprising the amino acid sequence SEQ ID NO:65.

[0175] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-LIGHT antibody comprises V H, the V H Comprising the amino acid sequence SEQ ID NO: 50, and V L , the V L Comprising the amino acid sequence SEQ ID NO:65.

[0176] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 51 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 51; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 63. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 51, and V L , the V L Comprising the amino acid sequence SEQ ID NO:63.

[0177] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 52 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 52; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 52, and V L , the V L Comprising the amino acid sequence SEQ ID NO:65.

[0178] In some embodiments, the anti-LIGHT antibody comprises: VH , the V H comprising the amino acid sequence of SEQ ID NO: 53 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 53; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 53, and V L , the V L Comprising the amino acid sequence SEQ ID NO:65.

[0179] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 51 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 51; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 51, and V L , the V L Comprising the amino acid sequence SEQ ID NO:65.

[0180] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17, or the V HA variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 24, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0181] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:24, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:31, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:38.

[0182] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:54 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 66 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0183] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 54 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 54; and V L , the V Lcomprising the amino acid sequence of SEQ ID NO: 66 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 66. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 54, and V L , the V L Comprising the amino acid sequence SEQ ID NO:66.

[0184] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 25, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0185] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:25, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:31, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:39.

[0186] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:55 HHC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 67 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0187] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 55 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 55; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 67 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 67. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 55, and V L , the V L Comprising the amino acid sequence SEQ ID NO:67.

[0188] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 40, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0189] In some embodiments, the anti-LIGHT antibody comprises V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:26, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:32, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:40.

[0190] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:56 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 68 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0191] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 56 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 56; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 68 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 68. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 56, and V L , the V L Comprising the amino acid sequence SEQ ID NO:68.

[0192] In some embodiments, the anti-LIGHT antibody comprises V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 41, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0193] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:26, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:32, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:41.

[0194] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 57 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 69 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0195] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 57 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 57; and V L , the VL comprising the amino acid sequence of SEQ ID NO: 69 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 69. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 57, and V L , the V L Comprising the amino acid sequence SEQ ID NO:69.

[0196] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 4, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 12, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 19, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 27, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 33, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 42, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0197] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 4, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 19; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:27, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:33, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:42.

[0198] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 58 HHC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 70 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0199] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 58 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 58; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 70 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 70. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 58, and V L , the V L Comprising the amino acid sequence SEQ ID NO:70.

[0200] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 5, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 20, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 28, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0201] In some embodiments, the anti-LIGHT antibody comprises V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 5, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 20; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:28, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:34, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:43.

[0202] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 59 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 71 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0203] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 59 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 59; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 71 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 71. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 59, and V L , the V L Comprising the amino acid sequence SEQ ID NO:71.

[0204] In some embodiments, an isolated anti-LIGHT antibody is provided, comprising a heavy chain variable domain (V H ), the V Hcomprising a heavy chain complementarity determining region (HC-CDR) 1 comprising DHIMN (SEQ ID NO: 6); HC-CDR2 comprising RIYPVSGETNYNQKFMG (SEQ ID NO: 14); and HC-CDR3 comprising GSYYWNAMDY (SEQ ID NO: 21); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDSYMN (SEQ ID NO:29) or KASQSVDFDGESYMN (SEQ ID NO:83); a LC-CDR2 comprising SASNLES (SEQ ID NO:35); and a LC-CDR3 comprising QQSIEDPWT (SEQ ID NO:43).

[0205] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids.

[0206] In some embodiments, the anti-LIGHT antibody comprises V H , the V H It comprises: HC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO: 6, HC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO: 14, and HC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO: 21.

[0207] 1. In some embodiments, the anti-LIGHT antibody comprises V L , the V LComprising: LC-CDR1, which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 or 83 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2 or 3) amino acids; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO: 35 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2 or 3) amino acids; and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO: 43 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2 or 3) amino acids.

[0208] In some embodiments, the anti-LIGHT antibody comprises V L , the V L It comprises: LC-CDR1, which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 or 83, LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO: 35, and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO: 43.

[0209] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 or 83 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2 or 3) amino acids; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO: 35 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2 or 3) amino acids; and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO: 43 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2 or 3) amino acids.

[0210] In some embodiments, the anti-LIGHT antibody comprises V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and V L , the V L It comprises: LC-CDR1, which comprises the amino acid sequence shown in any one of SEQ ID NOs: 29 or 83, LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO: 35, and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO: 43.

[0211] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0212] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:29, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:35, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:43.

[0213] In some embodiments, the anti-LIGHT antibody comprises V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 83, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0214] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:83, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:35, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:43.

[0215] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 60, 84-85 H Contains HC-CDR1, HC-CDR2 and HC-CDR3, as well as V L , the V L Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 72, 86-91 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0216] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 60 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L, which comprises V as shown in the amino acid sequence SEQ ID NO: 72 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0217] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO: 85 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO:90 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0218] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 60, 84-85, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as shown in any one of SEQ ID NOs: 60, 84-85; and V L , the V L comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 72, 86-91 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 72, 86-91. In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 60, 84-85, and V L , the V L It comprises the amino acid sequence shown in any one of SEQ ID NOs: 72, 86-91.

[0219] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 60 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 60; and V L , the V Lcomprising the amino acid sequence of SEQ ID NO: 72 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 72. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 60, and V L , the V L Comprising the amino acid sequence SEQ ID NO:72.

[0220] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 86 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 86. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 84, and V L , the V L Comprising the amino acid sequence SEQ ID NO:86.

[0221] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 85 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 85; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 87 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 87. In some embodiments, the anti-LIGHT antibody comprises V H , the VH Comprising the amino acid sequence SEQ ID NO: 85, and V L , the V L Comprising the amino acid sequence SEQ ID NO:87.

[0222] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 88 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 84, and V L , the V L Comprising the amino acid sequence SEQ ID NO:88.

[0223] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 89 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 89. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 84, and V L , the V L Comprising the amino acid sequence SEQ ID NO:89.

[0224] In some embodiments, the anti-LIGHT antibody comprises: V H, the V H comprising the amino acid sequence of SEQ ID NO: 85 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 85; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 90 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 90. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 85, and V L , the V L Comprising the amino acid sequence SEQ ID NO:90.

[0225] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 91 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 91. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 84, and V L , the V L Comprising the amino acid sequence SEQ ID NO:91.

[0226] In some embodiments, the anti-LIGHT antibody comprises a heavy chain variable domain (V H ), the V HThe heavy chain complementarity determining region (HC-CDR) 1 comprises SYNVH (SEQ ID NO: 7); HC-CDR2 comprises AVYPGNGDTSYNQKFKG (SEQ ID NO: 15); and HC-CDR3 comprises GSYYYTSSYFDH (SEQ ID NO: 22); and a light chain variable domain (V L ), the V L It comprises: a light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDSYMN (SEQ ID NO: 29); a LC-CDR2 comprising TASNLES (SEQ ID NO: 36); and a LC-CDR3 comprising QQSYEDPFT (SEQ ID NO: 44).

[0227] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids.

[0228] In some embodiments, the anti-LIGHT antibody comprises V H , the V H It comprises: HC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO: 7, HC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO: 15, and HC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO: 22.

[0229] In some embodiments, the anti-LIGHT antibody comprises V L , the V LComprising: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:29 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:36 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids; and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:44 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids.

[0230] In some embodiments, the anti-LIGHT antibody comprises V L , the V L It comprises: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:29, LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:36, and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:44.

[0231] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22 or a variant thereof, wherein the variant comprises a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and V L , the V L Comprising: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:29 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:36 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids; and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:44 or a variant thereof, wherein the variant comprises substitutions of up to about 3 (e.g., 1, 2 or 3) amino acids.

[0232] In some embodiments, the anti-LIGHT antibody comprises V H , the V Hcomprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and V L , the V L It comprises: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:29, LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:36, and LC-CDR3, which comprises the amino acid sequence shown in SEQ ID NO:44.

[0233] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15, HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22, or the V H A variant comprising up to about 5 amino acid substitutions in its HC-CDRs; and V L , the V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 36, LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 44, or the V L A variant comprising up to about 5 amino acid substitutions in its LC-CDRs.

[0234] In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:29, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:36, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:44.

[0235] In some embodiments, the anti-LIGHT antibody comprises V H , the V HComprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 61, 92-94 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , the V L Comprising V as shown in any one of the amino acid sequences of SEQ ID NOs: 73, 95-99 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0236] In some embodiments, the anti-LIGHT antibody comprises V H , which comprises V as shown in the amino acid sequence SEQ ID NO:61 H HC-CDR1, HC-CDR2 and HC-CDR3 included; and V L , which comprises V as shown in the amino acid sequence SEQ ID NO: 73 L Contains LC-CDR1, LC-CDR2 and LC-CDR3.

[0237] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 61, 92-94, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as shown in any one of SEQ ID NOs: 61, 92-94; and V L , the V L comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 73, 95-99 or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 73, 95-99. In some embodiments, the anti-LIGHT antibody comprises V H , the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 61, 92-94, and V L , the V L It comprises the amino acid sequence shown in any one of SEQ ID NOs: 73, 95-99.

[0238] In some embodiments, the anti-LIGHT antibody comprises: V H , the V Hcomprising the amino acid sequence of SEQ ID NO: 61 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 61; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 73 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 73. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 61, and V L , the V L Comprising the amino acid sequence SEQ ID NO:73.

[0239] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 95 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 95. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 92, and V L , the V L Comprising the amino acid sequence SEQ ID NO:95.

[0240] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 93 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 93; and V L , the V Lcomprising the amino acid sequence of SEQ ID NO: 96 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 96. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 93, and V L , the V L Comprising the amino acid sequence SEQ ID NO:96.

[0241] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 96 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 96. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 92, and V L , the V L Comprising the amino acid sequence SEQ ID NO:96.

[0242] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 97 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 97. In some embodiments, the anti-LIGHT antibody comprises V H , the VH Comprising the amino acid sequence SEQ ID NO: 94, and V L , the V L Comprising the amino acid sequence SEQ ID NO:97.

[0243] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 98 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 98. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 94, and V L , the V L Comprising the amino acid sequence SEQ ID NO:98.

[0244] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 93 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 93; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 98 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 98. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 93, and V L , the V L Comprising the amino acid sequence SEQ ID NO:98.

[0245] In some embodiments, the anti-LIGHT antibody comprises: V H, the V H comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 98 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 98. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 92, and V L , the V L Comprising the amino acid sequence SEQ ID NO:98.

[0246] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , the V L comprising the amino acid sequence of SEQ ID NO: 99 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 99. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 94, and V L , the V L Comprising the amino acid sequence SEQ ID NO:99.

[0247] In some embodiments, the anti-LIGHT antibody comprises: V H , the V H comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , the VL comprising the amino acid sequence of SEQ ID NO: 99 or a variant thereof having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence of SEQ ID NO: 99. In some embodiments, the anti-LIGHT antibody comprises V H , the V H Comprising the amino acid sequence SEQ ID NO: 92, and V L , the V L Comprising the amino acid sequence SEQ ID NO:99.

[0248] In some embodiments, the above-mentioned amino acid substitutions are limited to the "exemplary substitutions" shown herein in Table 4. In some embodiments, the amino acid substitutions are limited to the "preferred substitutions" shown herein in Table 4.

[0249] In some embodiments, functional epitopes can be resolved by combinatorial alanine scanning. In this process, combinatorial alanine scanning can be used to identify amino acids in the LIGHT protein that are necessary for interaction with the anti-LIGHT antibody. In some embodiments, the epitope is conformational, and the crystal structure of the anti-LIGHT antibody bound to the LIGHT protein can be used to identify the epitope.

[0250] In some embodiments, the present application provides antibodies that competitively bind to LIGHT with any of the anti-LIGHT antibodies described herein. In some embodiments, antibodies that can competitively bind to an epitope on LIGHT with any of the anti-LIGHT antibodies described herein are provided. In some embodiments, anti-LIGHT antibodies are provided that are combined with a V H and V L The anti-LIGHT antibody molecules bind to the same epitope, wherein the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 46-61, 92-94, and the V L In some embodiments, an anti-LIGHT antibody is provided, which is combined with a V H and V L The anti-LIGHT antibody competitively binds to LIGHT, wherein the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 46-61, 92-94, and the V L It comprises the amino acid sequence shown in any one of SEQ ID NOs: 62-73, 95-99.

[0251] In some embodiments, competition experiments can be used to identify monoclonal antibodies that compete with the anti-LIGHT antibodies described herein for binding to LIGHT. Competition experiments can determine whether two antibodies bind to the same epitope by recognizing the same or spatially overlapping epitopes or by competitively inhibiting the binding of one antibody to the antigen by another. In certain embodiments, such competing antibodies bind to the same epitope as the antibodies described herein. Some exemplary competition experiments include, but are not limited to, routine experiments such as those described in Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Detailed exemplary methods for analyzing epitopes bound by antibodies are described in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ). In some embodiments, if each antibody blocks 50% or more of the binding of the other antibody, it is said to bind to the same epitope. In some embodiments, the antibodies that compete with the anti-LIGHT antibodies described herein are chimeric, humanized, or fully human antibodies.

[0252] Exemplary anti-LIGHT antibody sequences are shown in Tables 2 and 3, where CDR numbering is performed according to the Kabat definition. Those skilled in the art will recognize that there are a variety of known algorithms for predicting the positions of CDRs and defining the variable regions of antibody light and heavy chains. H and / or V L Sequences, but based on prediction algorithms other than those exemplified in the table below, are also within the scope of this application.

[0253] Table 2 Exemplary anti-LIGHT antibody CDR sequences

[0254] Table 2A Exemplary Anti-LIGHT Antibody CDR Sequences

[0255] Table 2B Exemplary Anti-LIGHT Antibody CDR Sequences

[0256] Table 3 Exemplary sequences

[0257] Table 3A Exemplary sequences

[0258] Table 3B Exemplary sequences

[0259] LIGHT

[0260] LIGHT (a T-lymphocyte-inducible lymphotoxin-like receptor that competes with herpes simplex virus glycoprotein D for binding to HVEM), a member of the tumor necrosis factor superfamily (TNFSF), is a 240-amino acid type II transmembrane protein that forms a cell surface homotrimer. LIGHT is also known as tumor necrosis factor superfamily member 14 (TNFSF14), TL5, LTg, HVEML, or CD258. LIGHT is a T cell co-stimulatory molecule that can induce T cell proliferation and cytokine production (Tamada et al., 2000, Nat Med). LIGHT can also induce inflammatory responses in monocytes and endothelial cells (Otterda et al., 2006, Blood; Chang et al., 2005, J Biomed Sci). LIGHT binds to three different receptors expressed on different cell types: the herpes simplex virus entry regulator HVEM, expressed on T cells and B cells; the lymphotoxin β receptor LTβR, expressed on stromal cells and non-hematopoietic cells; and the decoy receptor 3. Light on dendritic cells and T cells enhances T cell proliferation and cytokine production. Light can directly co-stimulate T cell responses. The role of light in various inflammatory diseases and conditions has been demonstrated using various models of light-deficient models and light-overexpressing transgenic animals. Overexpression of light in mice leads to excessive overproduction of activated peripheral T cell populations and the spontaneous development of severe autoimmune diseases (Wang et al., 2001, J Clin Invest.).

[0261] LIGHT receptors

[0262] LIGHT mediates its biological effects by binding to three TNF superfamily receptors, including lymphotoxin beta receptor (LTβR) (Crowe et al., 1994, Science 264:707-10, Browning et al., 1997, J Immunol 159:3288-98), herpes simplex virus entry mediator (HVEM) (Montgomery et al., 1996, Cell 87(3)427-36), and decoy receptor 3 (DcR3) (Yu et al., 1999, J Biol Chem 274:13733-6).

[0263] Lymphotoxin beta receptor (LTβR) signaling coordinates lymphocyte neogenesis and subsequent tertiary lymphoid structures (TLS), and is associated with severe chronic inflammatory diseases in multiple organ systems. A study by Conlon TM et al. demonstrated that inhibition of the LTβR signaling pathway can activate Wnt-induced lung regeneration (Conlon TM et al., 2020, Nature 588(7836):151-156). The study demonstrated that in lung epithelial cells from patients with smoking-related chronic obstructive pulmonary disease (COPD) and mice exposed to chronic cigarette smoke, expression of LTβR ligands, including LTα, LTβ, and LIGHT, was increased on adaptive and innate immune cells, non-canonical NF-κB signaling was enhanced, and expression of LTβR target genes was enriched. Therapeutic inhibition of the LTβR signaling pathway using LTβR-Ig peptides in young and old mice disrupted smoking-related induced bronchus-associated lymphoid tissue (iBALT), induced lung tissue regeneration, and restored airway fibrosis and systemic muscle atrophy. Mechanistically, blockade of LTβR signaling inhibited epithelial non-canonical NF-κB activation and reduced TGFβ signaling in the airways, inducing regeneration by preventing epithelial cell death and activating Wnt / β-catenin signaling in alveolar epithelial progenitor cells.

[0264] LIGHT on activated T cells can directly transmit signals to other T cells expressing HVEM, or it can indirectly act through HVEM and / or LTβR expressed on immature DC cells or SC cells to stimulate these auxiliary cells to secrete proinflammatory factors. More and more experimental evidence shows that LIGHT expressed on DC or T cells can co-stimulate and enhance T cell proliferation and cytokine secretion (Tamada.K et al., 2000, J.Immunol.164,4105-4110.). Consistent with these reports, adding LIGHT-Ig recombinant fusion protein to T cells can activate NF-κB and AP-1, co-stimulate T cell proliferation and IFN-γ secretion (Granger et al., 2003, Cytokine Growth Factor Rev.14,289-296). This enhanced T cell activation is mediated by HVEM signaling because LTβR is not expressed on mature T cells. The interaction of LIGHT with HVEM expressed by other cell types can also trigger various functional activities. For example, soluble or membrane-bound LIGHT expressed on activated T cells, when contacted with HVEM expressed on immature DC cells, can induce DC cell maturation and enhance allogeneic stimulatory activity when CD40L-Ig is added (Morel et al., 2001, J. Immunol. 167, 2479-2486).

[0265] Studies have shown that transgenic mice that constitutively express LIGHT have been found to have hyperactivated T cell populations, which increases the risk of autoimmunity in mice, characterized by severe infiltration of effector cells in peripheral tissues (Wang et al., 2005, J Immunol 174 8173-82; Shaikh et al., 2001, J Immunol 167 6330-7; Wang et al., 2001, J Immunol 167 5099-105; Wang et al., 2004, J Clin Invest 113 826-35). The interaction between HVEM and LIGHT can promote the pathogenesis of graft-versus-host disease (GVHD). - / - or light - / - Transplantation of mouse allogeneic T cells into recipient mice induces a weakened anti-host CTL response, thereby prolonging the survival of the recipient mice. - / - and light - / - Donor T cells undergo apoptosis after transfer into recipient mice. Therefore, administration of anti-HVEM mAb can inhibit the HVEM-LIGHT interaction, improve GVHD response and prolong the survival of recipient mice (Xu et al., 2007, Blood 109:4097–4104). When mesenteric lymph node cells from LIGHT transgenic animals are transferred into RAG - / - When HVEM-LIGHT is expressed in the lungs, it can induce IBD-like symptoms, such as the cytokine signature of human Crohn's disease, ulcers, ileitis, and increased colonic IFN-γ and TNF (Wang et al., 2005, J Immunol 174 8173-82). In a T cell-dependent hypersensitivity pneumonitis model, HVEM-LIGHT interaction plays a dominant role in the survival of pathogenic memory Th2 cells. Disruption of the HVEM-LIGHT interaction inhibits the accumulation of inflammatory memory Th2 cells in the lungs. Although light - / - Donor CD4+ T cells were unable to survive antigen exposure in vivo, but co-transfer of wild-type and light- / - donor T cells rescued the survival defect of light- / - donor T cells, indicating that HVEM induces cell survival signals into T cells by interacting with LIGHT expressed on neighboring antigen-specific T cells. This study suggests that HVEM expressed by CD4+ T cells can induce cell survival signals and control T cell-driven hypersensitivity pneumonitis (Soroosh et al., 2011, J Exp Med 208:797–809).

[0266] DcR3, also known as tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), is a functional attenuator of light signaling. It is found in the human genome but absent in mice and rats. It lacks a membrane anchor and functions as a soluble inhibitor by binding to light, Fas ligand, and TL1A. In humans, DcR3 binds to light and inhibits the interaction between HVEM and light (Jiang M. 2016, Med Sci Monit. 22:1850–7).

[0267] Full-length anti-LIGHT antibody

[0268] In some embodiments, the anti-LIGHT antibody is a full-length anti-LIGHT antibody. In some embodiments, the full-length anti-LIGHT antibody is IgA, IgD, IgE, IgG or IgM. In some embodiments, the full-length anti-LIGHT antibody comprises an IgG constant region, such as a constant region of IgG1, IgG2, IgG3, IgG4 or a variant thereof. In some embodiments, the full-length anti-LIGHT antibody comprises a lambda light chain constant region. In some embodiments, the full-length anti-LIGHT antibody comprises a kappa light chain constant region. In some embodiments, the full-length anti-LIGHT antibody is a full-length human anti-LIGHT antibody. In some embodiments, the full-length anti-LIGHT antibody comprises a mouse immunoglobulin Fc sequence. In some embodiments, the full-length anti-LIGHT antibody comprises an altered or otherwise altered Fc sequence such that it has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effector functions.

[0269] Thus, for example, in some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided that specifically binds to LIGHT. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0270] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG2 constant region is provided, wherein the anti-LIGHT antibody specifically binds to LIGHT. In some embodiments, the IgG2 is a human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0271] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG3 constant region is provided, wherein the anti-LIGHT antibody specifically binds to LIGHT. In some embodiments, the IgG3 is a human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0272] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody specifically binds to LIGHT. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0273] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 1-7 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; an HC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 8-15 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and an HC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 16-22 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and b) a light chain variable domain comprising: an LC-CDR1 comprising an amino acid sequence as shown in any one of SEQ ID NOs: NOs: 23-29, 83 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids, LC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 30-36 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and LC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 37-44 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:77.

[0274] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG2 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 1-7 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; an HC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 8-15 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and an HC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 16-22 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and b) a light chain variable domain comprising: an LC-CDR1 comprising an amino acid sequence as shown in any one of SEQ ID NOs: NOs: 23-29, 83 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; LC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 30-36 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and LC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 37-44 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids. In some embodiments, the IgG2 is a human IgG2. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0275] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG3 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 1-7 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions, an HC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 8-15 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and an HC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 16-22 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and b) a light chain variable domain comprising: an LC-CDR1 comprising an amino acid sequence as shown in any one of SEQ ID NOs: NOs: 23-29, 83 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; LC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 30-36 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids; and LC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 37-44 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids. In some embodiments, the IgG3 is a human IgG3. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0276] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 1-7 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; an HC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 8-15 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and an HC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 16-22 or a variant thereof, wherein the variant comprises up to about 3 (e.g., 1, 2, or 3) amino acid substitutions; and b) a light chain variable domain comprising: an LC-CDR1 comprising an amino acid sequence as shown in any one of SEQ ID NOs: NOs: 23-29, 83 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids, LC-CDR2 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 30-36 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids, and LC-CDR3 comprising an amino acid sequence as shown in any one of SEQ ID NOs: 37-44 or a variant thereof, the variant comprising a substitution of up to about 3 (e.g., 1, 2, or 3) amino acids. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:77.

[0277] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-7, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 8-15, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 16-22, or a variant of the heavy chain variable domain comprising up to about 5 (e.g., 1, 2, 3, 4, or 5) amino acid substitutions in the HC-CDR sequence; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 23-29, 83, an LC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 30-36, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NOs: NOs:37-44, or a variant of the light chain variable domain, comprising a substitution of up to about 5 (e.g., 1, 2, 3, 4, or 5) amino acids in its LC-CDR sequence. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:77.

[0278] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-7, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 8-15, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 16-22, or a variant of the heavy chain variable domain comprising up to about 5 (e.g., 1, 2, 3, 4, or 5) amino acid substitutions in the HC-CDR sequence; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 23-29, 83, an LC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 30-36, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NOs: NOs:37-44, or a variant of the light chain variable domain, comprising a substitution of up to about 5 (e.g., 1, 2, 3, 4, or 5) amino acids in its LC-CDR sequence. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:77.

[0279] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-7, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 8-15, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 16-22; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 23-29, 83, an LC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 30-36, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 37-44. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0280] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 1-7, an HC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 8-15, and an HC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 16-22; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 23-29, 83, an LC-CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 30-36, and an LC-CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 37-44. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0281] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0282] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0283] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 24, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0284] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 25, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0285] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 40. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0286] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 41. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0287] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 19; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 27, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 33, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 42. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0288] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 20; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 28, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0289] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0290] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 83, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0291] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 36, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 44. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0292] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0293] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0294] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 24, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0295] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 25, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0296] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 40. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0297] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 41. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0298] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 19; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 27, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 33, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 42. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0299] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 5, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 20; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 28, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0300] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0301] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 83, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0302] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a) a heavy chain variable domain comprising: an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and b) a light chain variable domain comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 36, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 44. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0303] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94; and a light chain variable domain (V L ), the V Lcomprising the amino acid sequence of any one of SEQ ID NOs: 62-73, 86-91, 95-99, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 62-73, 86-91, 95-99. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:77.

[0304] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG2 constant region is provided, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94; and a light chain variable domain (V L ), the V L The invention also provides an IgG2 antibody comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 62-73, 86-91, 95-99, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 62-73, 86-91, 95-99. In some embodiments, the IgG2 antibody is a human IgG2 antibody. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0305] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG3 constant region is provided, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94; and a light chain variable domain (V L ), the V L The invention also provides an IgG3 antibody comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 62-73, 86-91, 95-99, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 62-73, 86-91, 95-99. In some embodiments, the IgG3 antibody is a human IgG3 antibody. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0306] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H comprising an amino acid sequence as shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence as shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94; and a light chain variable domain (V L ), the V Lcomprising the amino acid sequence of any one of SEQ ID NOs: 62-73, 86-91, 95-99, or a variant thereof, wherein the variant has at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 62-73, 86-91, 95-99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO:77.

[0307] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (V H ), the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94, and a light chain variable domain (V L ), the V L comprising the amino acid sequence of any one of SEQ ID NOs: 62-73, 86-91, 95-99. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0308] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: a heavy chain variable domain (VH ), the V H comprising the amino acid sequence shown in any one of SEQ ID NOs: 46-61, 84-85, 92-94, and a light chain variable domain (V L ), the V L comprising the amino acid sequence of any one of SEQ ID NOs: 62-73, 86-91, 95-99. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0309] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 46 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 46; and V L , which comprises the amino acid sequence of SEQ ID NO: 62 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 62. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0310] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0311] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0312] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0313] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0314] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , which comprises the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0315] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , which comprises the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0316] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , which comprises the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0317] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , which comprises the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0318] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , which comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0319] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , which comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0320] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , which comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0321] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , which comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0322] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 51 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 51; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0323] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 52 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 52; and V L , which comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0324] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 53 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 53; and V L , which comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0325] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 51 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 51; and V L , which comprises the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 65. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0326] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 54 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 54; and V L , which comprises the amino acid sequence of SEQ ID NO: 66 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 66. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0327] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 55 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 55; and V L , which comprises the amino acid sequence of SEQ ID NO: 67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 67. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0328] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 56 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 56; and V L , which comprises the amino acid sequence of SEQ ID NO: 68 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 68. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0329] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 57 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 57; and V L , which comprises the amino acid sequence of SEQ ID NO: 69 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 69. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0330] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 58 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 58; and V L , which comprises the amino acid sequence of SEQ ID NO: 70 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 70. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0331] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 59 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 59; and V L , which comprises the amino acid sequence of SEQ ID NO: 71 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 71. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0332] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 60 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 60; and V L , which comprises the amino acid sequence of SEQ ID NO: 72 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 72. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0333] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , which comprises the amino acid sequence of SEQ ID NO: 86 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 86. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0334] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 85 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 85; and V L , which comprises the amino acid sequence of SEQ ID NO: 87 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 87. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0335] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , which comprises the amino acid sequence of SEQ ID NO: 88 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 88. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0336] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , which comprises the amino acid sequence of SEQ ID NO: 89 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 89. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0337] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 85 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 85; and V L , which comprises the amino acid sequence of SEQ ID NO: 90 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 90. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0338] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , which comprises the amino acid sequence of SEQ ID NO: 91 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 91. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0339] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 61 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 61; and V L , which comprises the amino acid sequence of SEQ ID NO: 73 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 73. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0340] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , which comprises the amino acid sequence of SEQ ID NO: 95 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 95. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0341] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 93 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 93; and V L , which comprises the amino acid sequence of SEQ ID NO: 96 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 96. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0342] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , which comprises the amino acid sequence of SEQ ID NO: 96 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 96. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0343] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , which comprises the amino acid sequence of SEQ ID NO: 97 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 97. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0344] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , which comprises the amino acid sequence of SEQ ID NO: 98 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 98. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0345] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 93 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 93; and V L , which comprises the amino acid sequence of SEQ ID NO: 98 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 98. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0346] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , which comprises the amino acid sequence of SEQ ID NO: 98 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 98. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0347] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , which comprises the amino acid sequence of SEQ ID NO: 99 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0348] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG1 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , which comprises the amino acid sequence of SEQ ID NO: 99 or a variant thereof having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 99. In some embodiments, the IgG1 is a human IgG1. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 74 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0349] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 46 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 46; and V L , which comprises the amino acid sequence of SEQ ID NO: 62 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 62. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0350] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0351] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0352] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0353] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , which comprises the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 63. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 76. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75 and the light chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 77.

[0354] In some embodiments, a full-length anti-LIGHT antibody comprising an IgG4 constant region is provided, wherein the anti-LIGHT antibody comprises: V H, comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , which comprises the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 64. In some embodiments, the IgG4 is a human IgG4. In some embodiments, the heavy chain constant region comprises or consists of the amino acid sequence of SEQ ID NO: 75. In some embodiments, the light chain constant region comprises or consists of the ami...

Claims

1. An isolated anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: Heavy chain variable domain (V H ), the V H Include: heavy chain complementarity determining region (HC-CDR) 1, comprising GYFIN (SEQ ID NO: 1); HC-CDR2 comprising RIYPYNVNTFYNQNFKG (SEQ ID NO: 8) or RIYPYNVDTFYNQNFKG (SEQ ID NO: 9); and HC-CDR3 comprising GTHYYGSSGAMDY (SEQ ID NO: 16); and Light chain variable domain (V L ), the V L Include: Light chain complementarity determining region (LC-CDR) 1 comprising KASQNVGTAVA (SEQ ID NO: 23); LC-CDR2 comprising SASNRYT (SEQ ID NO: 30); and LC-CDR3 comprising QQYSSYPYT (SEQ ID NO: 37).

2. The isolated anti-LIGHT antibody according to claim 2, comprising: (i)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 23, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 37; or (ii)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:23, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:30, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:

37.

3. The isolated anti-LIGHT antibody according to any one of claims 1-2, comprising: (i)V H , comprising the amino acid sequence of SEQ ID NO: 46 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 46; and V L , comprising the amino acid sequence of SEQ ID NO: 62 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 62; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , which comprises the amino acid sequence SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; (iii)V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; (v)V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; (vi)V H , comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; (vii)V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; (viii)V H , comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; (ix)V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , comprising the amino acid sequence of SEQ ID NO: 64 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 64; (x)V H , comprising the amino acid sequence of SEQ ID NO: 47 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 47; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; (xi)V H , comprising the amino acid sequence of SEQ ID NO: 48 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 48; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; (xii)V H , comprising the amino acid sequence of SEQ ID NO: 49 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 49; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; (xiii)V H , comprising the amino acid sequence of SEQ ID NO: 50 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 50; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; (xiv)V H , comprising the amino acid sequence of SEQ ID NO: 51 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 51; and V L , comprising the amino acid sequence of SEQ ID NO: 63 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 63; (xv)V H , comprising the amino acid sequence of SEQ ID NO: 52 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 52; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; (xvi)V H , comprising the amino acid sequence of SEQ ID NO: 53 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 53; and V L , comprising the amino acid sequence of SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 65; or (xvii)V H , comprising the amino acid sequence of SEQ ID NO: 51 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 51; and V L , which comprises the amino acid sequence SEQ ID NO: 65 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:

65.

4. An isolated anti-LIGHT antibody comprising: (i)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 24, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 38; (ii)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 25, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 31, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 39; (iii)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 40; (iv)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 18; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 26, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 41; (v)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 4, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 19; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 27, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 33, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 42; or (vi)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 5, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 20; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:28, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:34, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:

43.

5. The isolated anti-LIGHT antibody according to claim 4, comprising: (i)V H , comprising the amino acid sequence of SEQ ID NO: 54 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 54; and V L , comprising the amino acid sequence set forth in SEQ ID NO: 66 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO: 66; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 55 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 55; and V L , comprising the amino acid sequence set forth in SEQ ID NO: 67 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO: 67; (iii)V H , comprising the amino acid sequence of SEQ ID NO: 56 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 56; and V L , comprising the amino acid sequence set forth in SEQ ID NO: 68 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO: 68; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 57 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 57; and V L , comprising the amino acid sequence set forth in SEQ ID NO: 69 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence set forth in SEQ ID NO: 69; (v)V H , comprising the amino acid sequence shown in SEQ ID NO: 58 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 58; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 70 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 70; or (vi)V H , comprising the amino acid sequence shown in SEQ ID NO: 59 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO: 59; and V L , which comprises the amino acid sequence shown in SEQ ID NO: 71 or a variant thereof, wherein the variant has at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:

71.

6. An isolated anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: Heavy chain variable domain (V H ), the V H Include: heavy chain complementarity determining region (HC-CDR) 1, comprising DHIMN (SEQ ID NO: 6); HC-CDR2 comprising RIYPVSGETNYNQKFMG (SEQ ID NO: 14); and HC-CDR3 comprising GSYYWNAMDY (SEQ ID NO: 21); and Light chain variable domain (V L ), the V L Include: Light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDSYMN (SEQ ID NO: 29) or KASQSVDFDGESYMN (SEQ ID NO: 83); LC-CDR2 comprising SASNLES (SEQ ID NO: 35); and LC-CDR3 comprising QQSIEDPWT (SEQ ID NO: 43).

7. The isolated anti-LIGHT antibody according to claim 6, comprising: (i)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and V L , the V L comprising: an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 29, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 43; or (ii)V H , the V H comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 6, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 21; and V L , the V L It comprises: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:83, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:35, and LC-CDR3 comprising the amino acid sequence of SEQ ID NO:

43.

8. The isolated anti-LIGHT antibody according to any one of claims 6-7, comprising: (i)V H , comprising the amino acid sequence of SEQ ID NO: 60 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 60; and V L , comprising the amino acid sequence of SEQ ID NO: 72 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 72; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , comprising the amino acid sequence of SEQ ID NO: 86 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 86; (iii)V H , comprising the amino acid sequence of SEQ ID NO: 85 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 85; and V L , which comprises the amino acid sequence SEQ ID NO:87 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:87; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , comprising the amino acid sequence of SEQ ID NO: 88 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 88; (v)V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , comprising the amino acid sequence of SEQ ID NO: 89 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 89; (vi)V H , comprising the amino acid sequence of SEQ ID NO: 85 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 85; and V L , comprising the amino acid sequence of SEQ ID NO: 90 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 90; or (vii)V H , comprising the amino acid sequence of SEQ ID NO: 84 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 84; and V L , comprising the amino acid sequence of SEQ ID NO: 91 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:

91.

9. An isolated anti-LIGHT antibody, wherein the anti-LIGHT antibody comprises: Heavy chain variable domain (V H ), the V H Include: heavy chain complementarity determining region (HC-CDR) 1 comprising SYNVH (SEQ ID NO: 7); HC-CDR2 comprising AVYPGNGDTSYNQKFKG (SEQ ID NO: 15); and HC-CDR3 comprising GSYYYTSSYFDH (SEQ ID NO: 22); and Light chain variable domain (V L ), the V L Include: Light chain complementarity determining region (LC-CDR) 1 comprising KASQSVDFDGDSYMN (SEQ ID NO: 29); LC-CDR2 comprising TASNLES (SEQ ID NO: 36); and LC-CDR3 comprising QQSYEDPFT (SEQ ID NO: 44).

10. The isolated anti-LIGHT antibody according to claim 9, comprising: (i)V H , comprising the amino acid sequence of SEQ ID NO: 61 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 61; and V L , comprising the amino acid sequence of SEQ ID NO: 73 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 73; (ii)V H , comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , comprising the amino acid sequence of SEQ ID NO: 95 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 95; (iii)V H , comprising the amino acid sequence of SEQ ID NO: 93 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 93; and V L , comprising the amino acid sequence of SEQ ID NO: 96 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 96; (iv)V H , comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , comprising the amino acid sequence of SEQ ID NO: 96 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 96; (v)V H , comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , comprising the amino acid sequence of SEQ ID NO: 97 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 97; (vi)V H , comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , comprising the amino acid sequence of SEQ ID NO: 98 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 98; (vii)V H , comprising the amino acid sequence of SEQ ID NO: 93 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 93; and V L , comprising the amino acid sequence of SEQ ID NO: 98 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 98; (viii)V H , comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , which comprises the amino acid sequence SEQ ID NO: 98 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 98; (ix)V H , comprising the amino acid sequence of SEQ ID NO: 94 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 94; and V L , comprising the amino acid sequence of SEQ ID NO: 99 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 99; or (x)V H , comprising the amino acid sequence of SEQ ID NO: 92 or a variant thereof, said variant having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 92; and V L , comprising the amino acid sequence of SEQ ID NO: 99 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence of SEQ ID NO:

99.

11. The isolated anti-LIGHT antibody of any one of claims 1-10, wherein the anti-LIGHT antibody binds to human LIGHT with a Kd value of about 0.1 pM to about 10 nM.

12. The isolated anti-LIGHT antibody according to any one of claims 1 to 11, wherein the anti-LIGHT antibody comprises an Fc fragment.

13. The isolated anti-LIGHT antibody according to claim 12, wherein the anti-LIGHT antibody is a full-length IgA, IgD, IgE, IgG or IgM antibody.

14. The isolated anti-LIGHT antibody according to claim 13, wherein the anti-LIGHT antibody is a full-length IgG1, IgG2, IgG3 or IgG4 antibody.

15. The isolated anti-LIGHT antibody according to any one of claims 1 to 14, wherein the anti-LIGHT antibody is a chimeric, human or humanized antibody.

16. The isolated anti-LIGHT antibody according to any one of claims 1 to 11, wherein the anti-LIGHT antibody is an antigen-binding fragment selected from the group consisting of Fab, Fab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, diabody and linear antibody.

17. An isolated nucleic acid molecule encoding the anti-LIGHT antibody of any one of claims 1-16.

18. A vector comprising the nucleic acid molecule of claim 17.

19. An isolated host cell comprising the anti-LIGHT antibody of any one of claims 1 to 16, the nucleic acid molecule of claim 17, or the vector of claim 18.

20. A method for preparing an anti-LIGHT antibody, comprising: a) culturing the host cell of claim 19 under conditions that effectively express the anti-LIGHT antibody; and b) Obtaining the expressed anti-LIGHT antibody from the host cells.

21. A pharmaceutical composition comprising the anti-LIGHT antibody of any one of claims 1 to 16, the nucleic acid molecule of claim 17, the vector of claim 18, the isolated host cell of claim 19 or the antibody produced by the method of claim 20, and a pharmaceutically acceptable carrier.

22. A method of treating a disease or condition in an individual in need thereof, comprising administering to the individual an effective amount of the antibody of any one of claims 1-16, the nucleic acid molecule of claim 17, the vector of claim 18, the host cell of claim 19, the antibody produced by the method of claim 20, or the pharmaceutical composition of claim 21.

23. Use of the antibody of any one of claims 1 to 16, the nucleic acid molecule of claim 17, the vector of claim 18, the host cell of claim 19, the antibody produced by the method of claim 20, or the pharmaceutical composition of claim 21 in the preparation of a medicament for treating a disease or condition in an individual in need thereof.

24. The method according to claim 22 or the use according to claim 23, wherein the disease or disorder is a disease and / or disorder caused by dysregulation of the LIGHT signaling pathway, such as an autoimmune disease and / or an inflammatory disease.

25. The method of claim 22 or the use of claim 23, wherein the disease or condition is selected from inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, ankylosing spondylitis, atopic dermatitis, rheumatoid arthritis, bronchiolitis, transplant rejection, allograft rejection, graft-versus-host disease (GVHD), asthma, eosinophilic esophagitis, acute respiratory distress syndrome (ARDS), chronic heart failure, chronic obstructive pulmonary disease (COPD), septic shock, fibrotic diseases, skin fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, chronic kidney disease, systemic sclerosis, multiple sclerosis, Sjogren's syndrome, lupus, airway inflammation, psoriasis, hepatitis, celiac disease, primary biliary cirrhosis, autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenic purpura, non-alcoholic fatty liver disease, COVID19.

Images